[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":507},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,61,0,25,[9,42,64,86,104,124,144,165,187,200,222,242,261,279,298,319,337,356,375,393,411,431,452,471,490],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053436",false,"NCT07608666","Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets","A Single-center, Open-label, Single-dose, Fixed-dose Regimen, Self-controlled Phase I Clinical Trial to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the pH-dependent Pharmacokinetics of TQ05105 Tablets","Inclusion Criteria:\n\n* Signed informed consent prior to the study, fully understood the study content, procedures and potential adverse reactions; able to complete the study per protocol requirements.\n* The participant (including partner) agrees not to plan pregnancy, sperm donation or egg donation from screening until 6 months after the last study drug administration, and is willing to use effective contraception.\n* Healthy male and female participants aged 18-45 years (inclusive).\n* Male body weight ≥ 50.0 kg; female body weight ≥ 45.0 kg.BMI = weight (kg)\u002Fheight² (m²), range 18.0-28.0 kg\u002Fm² (inclusive).\n\nExclusion Criteria:\n\n* Participants with clinically significant abnormalities in vital signs, physical examination, ECG or clinical laboratory tests, and deemed unsuitable for participation by the investigator.\n* Participants with severe or chronic diseases of the circulatory, digestive, respiratory, urinary, nervous, hematologic, endocrine\u002Fmetabolic, neoplastic, immune or psychiatric systems within the past 1 year or currently, or any other disease that may interfere with study results.\n* Platelet count or absolute neutrophil count below the lower limit of the reference range at screening.\n* Any disease increasing bleeding risk, such as hemorrhoids, acute gastritis, gastric or duodenal ulcer.\n* Alanine aminotransferase (ALT) \\> 1.2×ULN, aspartate aminotransferase (AST) \\> 1.2×ULN, alkaline phosphatase (ALP) \\> 1.2×ULN, total bilirubin (TBIL) \\> 1.2×ULN, or any clinically significant abnormality judged by the investigator.\n* Any malignancy within the past 5 years.\n* Any condition that may affect absorption, distribution, metabolism or excretion of study drug (e.g., inability to swallow), or history of gastrointestinal resection that may affect drug disposition.\n* Allergy to rabeprazole, TQ05105 or their excipients; or history of multiple allergies (≥2 substances), including drug allergy, and tendency to develop rash, eczema, urticaria, asthma, etc.\n* Use of any strong or moderate inducers or inhibitors of CYP3A4, CYP2C9 and CYP2C19 within 4 weeks prior to screening.\n* Use of any prescription drugs, over the counter medications, herbal medicines or dietary supplements (e.g., vitamins, calcium supplements) within 4 weeks prior to screening.\n* Use of any acid suppressive therapy within 3 months prior to screening.\n* Participation in any clinical trial involving investigational drugs within 3 months prior to screening or within 5 half lives of the study drug (whichever is longer).\n* Positive results for HIV antibody, hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV) or syphilis antibody.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 90 mL\u002Fmin\u002F1.73m² at screening.\n* Average daily cigarette consumption \\>5 cigarettes within 3 months prior to screening.\n* History of drug abuse within 3 months prior to screening, or positive urine drug screen.\n* Regular alcohol consumption within 3 months prior to screening (≥14 units\u002Fweek; 1 unit = 360 mL beer \u002F 45 mL 40% spirits \u002F 150 mL wine), or positive alcohol breath test.\n* Blood donation or blood loss ≥200 mL, or plasma exchange within 4 weeks prior to screening.\n* Consumption of alcohol (or positive alcohol breath test), grapefruit juice, coffee, tea, cola, chocolate or related food\u002Fbeverage within 72 hours before dosing.\n* Pregnant or breastfeeding female participants, positive serum pregnancy test, or unprotected sexual intercourse within 2 weeks prior to screening for women of childbearing potential.\n* Strenuous exercise (e.g., marathon, weightlifting) within 2 weeks prior to screening.\n* Any other condition deemed unsuitable for participation by the investigator.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},17,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Primary objective:\n\nTo evaluate the effect of rabeprazole on the primary pharmacokinetics of TQ05105 tablets.\n\nSecondary objective:\n\nTo assess the safety and tolerability of single oral administration of TQ05105 tablets alone and in combination with rabeprazole in healthy study participants.\n\nTo evaluate the effect of rabeprazole on the secondary PK parameters of TQ05105 and the pharmacokinetics of its active metabolite TQ12550.",[28],"Myelofibrosis","NOT_YET_RECRUITING","2026-07-09",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":22},"2026-07",{"date":37,"type":22},"2026-12",{"name":39,"class":40},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",1,{"id":43,"slug":4,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100053751","NCT07697443","Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects","Phase I\u002FII Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3126 in Subjects With Breast Cancer","Inclusion Criteria:\n\n1. Subjects voluntarily participate in this study, sign the informed consent form, and demonstrate good treatment compliance.\n2. Aged 18 to 75 years at the time of informed consent signature; Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; estimated survival expectancy of more than 3 months.\n3. Histopathologically confirmed breast cancer.\n4. Documented disease progression confirmed by clinical or imaging evidence during or after the most recent prior systemic therapy prior to the first study drug administration.\n5. Have evaluable lesions per RECIST v1.1 criteria (measurable lesions; or bone-only metastases with at least one osteolytic or mixed lesion).\n6. Adequate tissue samples shall be provided at screening for gene mutation testing to clarify genetic status.\n7. Laboratory test results meet the criteria specified in the protocol (blood routine, liver and renal function, coagulation function, cardiac ultrasound Left Ventricular Ejection Fraction(LVEF) and other indicators are all within the protocol-specified ranges).\n8. Subjects of childbearing potential must agree to use effective contraceptive measures throughout the study and for 6 months after study completion (the same requirement applies to male subjects); serum or urine pregnancy test result is negative within 7 days prior to enrollment.\n\nExclusion Criteria:\n\n1. Other malignant tumors within 5 years prior to first dose, except those cured by single surgical treatment with at least 5 years of disease-free survival, or cured differentiated thyroid cancer, cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder tumors.\n2. Conditions affecting intravenous access or blood sampling, or multiple factors affecting oral drug administration\u002Fabsorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction).\n3. Unresolved toxicity from prior therapy of Grade \\>1 (CTCAE v6.0), except Grade 2 alopecia, Grade 2 anemia, clinically insignificant laboratory abnormalities, or hypothyroidism stable on hormone replacement therapy.\n4. Major surgery, significant traumatic injury within 4 weeks before first dose, anticipated need for major surgery during the study, or long-standing unhealed fracture.\n5. Any bleeding event of Grade \\>=3 within 4 weeks before first dose.\n6. Arterial\u002Fvenous thrombotic events within 6 months before first dose (e.g., cerebrovascular accident, deep vein thrombosis, pulmonary embolism), excluding catheter-related or superficial venous thrombosis.\n7. Active viral hepatitis that is poorly controlled (Hepatitis B Virus (HBV)\u002FHepatitis C Virus (HCV)-infected subjects meeting protocol-specified criteria may be enrolled).\n8. Active syphilis infection requiring treatment.\n9. Active tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or radiation pneumonitis requiring treatment, or history of\u002Fcurrent interstitial lung disease (ILD).\n10. History of psychotropic substance abuse unable to be discontinued, mental disorders, epilepsy requiring treatment, or severe psychiatric\u002Fneurological disease.\n11. Planned or prior allogeneic bone marrow or solid organ transplantation.\n12. Decompensated cirrhosis (Child-Pugh Class B or C) or history of hepatic encephalopathy.\n13. Significant cardiovascular disease, including New York Heart Association(NYHA) Class \\>II heart failure, clinically significant ventricular arrhythmia, unstable angina, myocardial infarction within 12 months, markedly prolonged QT interval corrected by Fridericia's formula (QTcF), or personal\u002Ffamily history of congenital long QT syndrome.\n14. Poorly controlled hypertension (resting systolic BP \\>=160 mmHg or diastolic BP \\>=100 mmHg on at least 2 measurements \\>=24 hours apart).\n15. Active or uncontrolled serious infection (Grade \\>=2).\n16. Renal failure requiring hemodialysis or peritoneal dialysis; or history of\u002Fcurrent nephrotic syndrome (except cured) or chronic nephritis.\n17. History of immunodeficiency, including HIV infection or other acquired\u002Fcongenital immunodeficiency diseases.\n18. Poorly controlled autoimmune disease requiring immunosuppressants or systemic corticosteroids for immunosuppression, continued within 7 days before first dose (except low-dose corticosteroids).\n19. Clinically significant endometrial abnormalities (including hyperplasia, dysfunctional uterine bleeding, etc.).\n20. Tumor-related conditions\u002Ftreatments: anti-cancer therapy within 3 weeks before first dose or still within the drug's washout period; prior local radiotherapy not meeting protocol-specified interval or target lesion requirements; use of National Medical Products Administration (NMPA)-approved proprietary Chinese medicine with anti-tumor indications within 1 week before first dose; imaging showing tumor invasion of major vessels with risk of fatal hemorrhage; uncontrolled pleural effusion\u002Fascites\u002Fmoderate-or-greater pericardial effusion requiring repeated drainage; known leptomeningeal metastasis or uncontrolled brain metastasis symptoms; severe skeletal-related events due to bone metastases.\n21. Known hypersensitivity to the study drug or its excipients.\n22. Participation in and use of another investigational anti-tumor drug within 4 weeks before first dose.\n23. Any concomitant disease or condition that, in the investigator's judgment, seriously endangers subject safety or study compliance, or any other reason making the subject unsuitable for enrollment.","75 Years",{"count":50,"type":22},306,[25,52],"PHASE2","The trial comprises Phase I dose escalation\u002Fexpansion and Phase II combination therapy. Using a multicenter, open-label, non-randomized design, breast cancer patients will receive TQB3126 to assess its safety, tolerability, pharmacokinetics and preliminary efficacy.",[55],"Breast Cancer","2026-07-07",{"date":32,"type":33},{"date":59,"type":22},"2026-08",{"date":61,"type":22},"2030-08",{"name":39,"class":40},6,{"id":65,"slug":4,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":70,"targetDuration":4,"studyType":23,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100621199","NCT07367516","Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","A Phase Ib\u002FII Clinical Trial Evaluating the Safety and Efficacy of TQB6411 Injection in Participant s With Recurrent or Metastatic Esophageal Cancer Who Have Failed Prior PD-1\u002FPD-L1 Inhibitor Plus Platinum-Based Chemotherapy","Inclusion Criteria:\n\n* Participants voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance.\n* Age between 18 and 75 years old (inclusive)\n* Eastern Cooperative Oncology Group (ECOG) score of 0-1\n* Expected survival \\>12 weeks\n* At least one measurable lesion per RECIST v1.1\n* Laboratory criteria(no hematopoietic growth factor correction within 7 days)：\n\n  * Hemoglobin (HGB) ≥90 g\u002FL;\n  * Absolute neutrophil count (NEUT) ≥1.5×10⁹\u002FL;\n  * Platelets (PLT) ≥90×10⁹\u002FL;\n  * Total bilirubin (TBIL) ≤1.5×ULN;\n  * Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) ≤2.5×ULN (≤5×ULN if liver metastases present);\n  * Serum creatinine (CR) ≤1.3×ULNorcreatinine clearance rate (CCR) ≥50 mL\u002Fmin;\n* Histologically\u002Fcytologically confirmed recurrent or metastatic Esophageal cancer\n* Failure\u002Fintolerance to prior PD-1\u002FPD-L1 inhibitor plus platinum-based chemotherapy for recurrent\u002Fmetastatic Esophageal Carcinoma (EC)\n* Willingness to provide archived or fresh tumor tissue for biomarker analysis.\n* Females of childbearing potential: Negative serum\u002Furine pregnancy test within 7 days before enrollment and agreement to use effective contraception during and for 6 months post-study. Males: Agreement to use effective contraception during and for 6 months post-study.\n\nExclusion Criteria:\n\n* Current or History of Other Malignancies\n* Participants with any condition that may compromise venous access for drug administration or blood sampling are excluded.\n* Participants with prior treatment-related adverse reactions that have not recovered to ≤ Grade 1 per CTCAE v5.0 criteria.\n* Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose, Scheduled major surgery during the study intervention period, Non-healing wound, ulcer, or bone fracture at screening\n* Participants with any bleeding\u002Fhemorrhagic event ≥ Grade 3 (per CTCAE v5.0) occurring within 4 weeks before the first dose are excluded\n* History of Thromboembolic Events within 6 Months\n* Poorly Controlled Active Viral Hepatitis\n* Participants with active syphilis infection requiring antimicrobial therapy are excluded\n* Participants with any of the following pulmonary conditions are excluded: active tuberculosis, idiopathic pulmonary fibrosis (IPF), organizing pneumonia, drug-induced\u002Fradiation pneumonitis requiring treatment, symptomatic active pneumonia, or history of interstitial lung disease (ILD) requiring therapy\n* History of Substance Abuse or Psychiatric Disorders\n* History of Allogeneic Transplantation (Bone Marrow or Solid Organ)\n* History of Hepatic Encephalopathy\n* Major Cardiovascular Diseases\n* Active or Uncontrolled Severe Infections\n* Renal Failure Requiring Dialysis (Hemodialysis\u002FPeritoneal Dialysis)\n* History of Immunodeficiency\n* Poorly Controlled Autoimmune Disease\n* Poorly Controlled Autoimmune Disease \\& Epilepsy Requiring Treatment\n* Poorly Controlled Diabetes\n* Tumor-Related Symptoms and Treatment Considerations：\n\n  * Exclusion Criterion - Recent Anticancer Treatment (≤3 Weeks or Within 5 Half-Lives)\n  * Recent Use of National Medical Products Administration (NMPA) -Approved Anticancer Traditional Chinese Medicine (≤1 Week Prior to Treatment)\n  * Radiologically Confirmed Tumor Encasement of Major Vessels with High Bleeding Risk\n  * Uncontrolled Effusions Requiring Repeated Drainage\n  * Known to have spinal cord compression, leptomeningeal metastasis\u002Fcarcinomatous meningitis, or symptomatic brain metastases with less than 4 weeks of symptom\u002Fimaging control.\n* Known Hypersensitivity to Investigational Drug or Excipients\n* Prior Treatment with Topoisomerase I Inhibitor-Based ADCs and\u002For Irinotecan Chemotherapy\n* Prior Participation in Anticancer Clinical Trials Within 4 Weeks\n* Investigator-Assessed Safety or Compliance Concerns",{"count":71,"type":22},105,[25,52],"The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1\u002FPD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of TQB6411 Injection in this same participants population.",[75],"Esophageal Cancer","RECRUITING","2026-06-30",{"date":79,"type":33},"2026-07-02",{"date":81,"type":33},"2026-02-12",{"date":83,"type":22},"2027-03",{"name":39,"class":40},30,{"id":87,"slug":4,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100643919","NCT07663331","A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis","Inclusion Criteria:\n\n* The subject must sign an informed consent form for data collection and data validation, and the research protocol\u002Finformed consent form must comply with local legal and regulatory requirements;\n* Age 18 or above, gender unrestricted;\n* Diagnosed with active non-infectious intermediate, posterior, or panuveitis, defined as the presence of at least one of the following conditions in at least one eye: active, inflammatory chorioretinopathy and\u002For inflammatory retinal vasculitis; ≥2+ AC cells (according to the Standardization of Uveitis Nomenclature \\[SUN\\] criteria); or ≥2+ VH (National Eye Institute\u002FSUN criteria);\n* The subject had received oral prednisone (or equivalent corticosteroid medication) at a dose of ≥10 mg to 60 mg\u002Fday for ≥2 weeks prior to screening and remained on the same dose at baseline, with corresponding documentation provided;\n* The subject (including their partner) agrees to have no pregnancy or sperm donation plans during the entire trial period and for six months after the study concludes, and voluntarily adopts effective contraceptive measures;\n* Adult subjects with non-infectious uveitis who were prescribed TEBOV® adalimumab injection by physicians after a thorough risk\u002Fbenefit assessment.\n\nExclusion Criteria:\n\n* (Based on the instructions for Tymphul® Adalimumab Injection and the judgment of the treating physician, the subject is not suitable for treatment with Tymphul® Adalimumab Injection.);\n* The subject had any of the following ocular events during screening: isolated anterior uveitis; confirmed or suspected infectious uveitis; ocular masquerade syndrome, such as ocular lymphoma; ocular histoplasmosis syndrome; serpiginous choroidopathy; scleritis; corneal or lens opacity impairing fundus visualization or requiring cataract surgery during the trial; macular edema as the sole sign of uveitis; severe VH impairing fundus visualization at baseline; intraocular pressure ≥25 mmHg with use of ≥2 glaucoma medications or evidence of glaucomatous optic neuropathy; best-corrected visual acuity (BCVA) of less than 20 letters (ETDRS) in either eye at baseline; proliferative or severe nonproliferative diabetic retinopathy or clinically significant macular edema caused by diabetic retinopathy; neovascular (wet) age-related macular degeneration; vitreoretinal interface abnormalities (e.g., vitreomacular traction, epiretinal membrane, etc.) that may lead to macular structural damage unrelated to inflammatory processes; ocular surgery performed within 90 days prior to the baseline visit, excluding refractive laser surgery, retinal laser photocoagulation, or Yttrium Aluminum Garnet (YAG) (neodymium-doped yttrium-aluminum-garnet) posterior capsulotomy;\n* The subject has any of the following medical conditions or diseases: current or past history of demyelinating diseases (including multiple sclerosis and optic neuritis) or neurological symptoms indicative of demyelinating diseases, including but not limited to optic neuritis; current or past history of systemic lupus erythematosus; arrhythmia (QTc ≥450ms for males, QTc ≥470ms for females); moderate to severe congestive heart failure (New York Heart Association Class III-IV); recent cerebrovascular accident and any other medical history deemed by the investigator to pose a risk to the subject's participation in the study; any malignant tumor (except successfully treated non-melanoma skin cancer or localized cervical carcinoma in situ); any other clinically significant medical condition that the investigator deems to interfere with the subject's participation in the study or render the subject ineligible for the investigational drug, or any other reason;\n* Individuals allergic to the active ingredients (and their excipients) and\u002For similar products;\n* During the screening period or baseline visit, individuals with systemic inflammatory diseases requiring continued oral corticosteroid therapy or immunosuppressive treatment;\n* Infections requiring intravenous antimicrobial treatment within 30 days prior to the baseline visit, or infections requiring oral antimicrobial treatment within 14 days prior to the baseline visit;\n* Within 30 days prior to the baseline, an increase in the dose of other concomitant immunosuppressive therapy or failure to meet any of the following conditions: methotrexate (MTX) ≤25 mg\u002Fweek; cyclosporine ≤4 mg\u002Fkg\u002Fday; mycophenolate (or equivalent dose of mycophenolic acid) ≤2 g\u002Fday; azathioprine ≤175 mg\u002Fday; tacrolimus oral ≤8 mg\u002Fday;Subjects who have received any live vaccine within 3 months prior to the first dose of Tadabow® Adalimumab injection, or who plan to receive live vaccines during the study;(7) Subjects currently participating in other clinical studies;\n* Subjects deemed unsuitable for participation in this trial by the investigator.\n* Within 90 days prior to baseline, intravitreal injection of anti Vascular Endothelial Growth Factor (VEGF) therapy (such as ranibizumab, aflibercept, or conbercept) has been administered;\n* Within 90 days prior to baseline, methotrexate was injected into the vitreous body for treatment;\n* Ozurdex implantation (dexamethasone implantation) was performed within 6 months prior to baseline;\n* Have received treatment with anti-tumor necrosis factor TNF or other potential therapeutic agents for uveitis within the past 6 months (excluding intravitreal injection of anti VEGF drugs);\n* After receiving the first dose of Taibowei ® Individuals who have received any live vaccine within the past 3 months prior to Adalimumab injection, or those who plan to receive a live vaccine during the study period;\n* Participants who are currently participating in other clinical studies;\n* Researchers believe that participants who are not suitable to participate in this trial.",{"count":85,"type":22},[93],"PHASE4","This study is a real-world clinical research on adalimumab. The project plans to enroll 30 subjects. The safety and efficacy of adalimumab injection for adult non-infectious uveitis are being investigated. The time of treatment failure for subjects at 6 weeks of treatment or between 6 and 24 weeks of treatment is the primary endpoint.",[96],"Adult Non-infectious Uveitis","2026-06-22",{"date":99,"type":33},"2026-06-25",{"date":35,"type":22},{"date":102,"type":22},"2028-02",{"name":39,"class":40},{"id":105,"slug":4,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100618993","NCT07338838","To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors","A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TQB3142 for Injection in Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* The subjects voluntarily joined the study, signed the informed consent, and had good compliance;\n* 18 years old ≤ age ≤75 years old (calculated on the date of signing the informed consent);\n* Eastern Cooperative Oncology Group Performance Status (ECOG) score 0\\~1;\n* Expected survival greater than 12 weeks;\n* Patients with advanced tumors confirmed by cytology\u002Fhistopathology, failure of standard treatment or lack of effective treatment;\n* Evidence of at least one evaluable lesion according to RECIST 1.1 criteria；\n* The main organs function well and meet the following criteria:\n\n  1. Hemoglobin (HGB) ≥80g\u002FL (Patients with myeloid neoplasms must have hemoglobin level ≥ 60 g\u002FL);\n  2. Absolute neutrophil count (ANC) of solid tumor subjects ≥1.5×109 \u002FL;\n  3. Platelet count (PLT) ≥80×109\u002FL (Patients with myeloid neoplasms must have a platelet count ≥ 30 × 10⁹\u002FL)；\n  4. Total bilirubin (TBIL) ≤1.5 times the upper limit of normal value (ULN);\n  5. Alanine transferase (ALT) and aspartate transferase (AST) ≤2.5×ULN. ALT and AST≤5×ULN if accompanied by liver metastasis;\n  6. Serum creatinine (CR) ≤1.5×ULN or creatinine clearance (CCR) ≥60 mL \u002Fmin (standard Cockcroft-Gault formula was applied;\n  7. Prothrombin time (PT), activated partial thromboplastin time (APTT), International standardized ratio (INR) ≤ 1.5×ULN (no anticoagulant therapy);\n* Women of reproductive age should agree that effective contraception must be used during the study period and for 6 months after the end of the study, and that serum or urine pregnancy tests are negative within 7 days prior to study enrollment; Men should agree that effective birth control must be used during the study period and for 6 months after the end of the study period.\n\nExclusion Criteria:\n\nI. Comorbid Conditions and Medical History:\n\n* Any active malignancy within the 3 years prior to the first dose, except for the specific cancer under study in this trial and locally recurrent cancers that have been cured (e.g., resected basal cell or squamous cell skin cancer, superficial bladder cancer \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the lamina propria)\\], carcinoma in situ of the cervix, or carcinoma in situ of the breast).\n* Failure to recover from toxicities and\u002For complications of prior interventions to ≤ Grade 1 per CTCAE, except for alopecia and peripheral neuropathy ≤ Grade 2.\n* Receipt of any blood product transfusion or requirement for hematopoietic growth factor therapy within 28 days prior to the first dose.\n* Bleeding Risk:\n\n  1. Known bleeding diathesis or disorder.\n  2. History of non-chemotherapy-induced thrombocytopenic bleeding or history of platelet transfusion refractoriness within 1 year prior to the first dose.\n  3. Presence or high suspicion of active bleeding\u002Fhemolytic disorders such as Immune Thrombocytopenic Purpura (ITP), Autoimmune Hemolytic Anemia (AIHA), Evans Syndrome, Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura (TTP), Disseminated Intravascular Coagulation (DIC).\n  4. Requirement for warfarin, aspirin, or other anticoagulant\u002Fantiplatelet agents for any reason within 28 days prior to treatment initiation.\n  5. Uncontrolled or CTCAE ≥ Grade 2 bleeding events (e.g., gastrointestinal bleeding) or history of hemoptysis (\\> 2.5 mL of fresh blood per day) within 90 days prior to the first dose.\n  6. Major surgical treatment or significant traumatic injury (excluding procedures like needle biopsy, endoscopic biopsy) within 28 days prior to the first dose.\n  7. Non-healing wounds or fractures (excluding pathological fractures).\n* Arterial\u002Fvenous thrombotic events within 6 months prior to the first dose, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism.\n* History of drug (psychoactive substances) or alcohol abuse with inability to abstain, or presence of psychiatric disorders.\n* Subjects with any severe and\u002For uncontrolled diseases, including:\n\n  1. Poorly controlled blood pressure (systolic BP ≥ 150 mmHg or diastolic BP ≥ 100 mmHg) despite treatment with two or more antihypertensive medications.\n  2. Myocardial ischemia or myocardial infarction ≥ Grade 2, arrhythmias, and congestive heart failure ≥ Grade 2 (NYHA classification).\n  3. History or presence of non-infectious pneumonitis requiring corticosteroid treatment (including but not limited to Acute Respiratory Distress Syndrome, Acute Hypersensitivity Pneumonitis, Drug-Related Pneumonitis, Bronchospasm, Acute Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, etc.).\n  4. History, presence, or suspicion of Chronic Obstructive Pulmonary Disease (COPD) with Forced Expiratory Volume in 1 second (FEV1) \\\u003C 60% of predicted value.\n  5. Active or uncontrolled severe infection (≥ CTCAE Grade 2 infection).\n  6. Diagnosis of Coronavirus Disease 2019 (COVID-19) infection within 3 months prior to the first dose.\n  7. Decompensated cirrhosis (Child-Pugh class B or C), active hepatitis:\n\n     * Hepatitis B reference: Hepatitis B Virus (HBV) - DNA \\> 1\\*10³ copies\u002FmL or \\>2000 IU\u002FmL if HBsAg positive.\n     * Hepatitis C reference: Hepatitis C Virus (HCV) RNA above the upper limit of normal.\n\n     (Note: Eligible subjects who are HBsAg positive or anti-Hepatitis B core (HBc) antigen positive, or have hepatitis C, require continuous antiviral therapy to prevent viral reactivation.)\n  8. Active syphilis.\n  9. Renal abnormalities:\n\n     * Renal failure requiring hemodialysis or peritoneal dialysis.\n     * History or presence of nephrotic syndrome (except if cured), chronic nephritis.\n  10. History of immunodeficiency, including HIV positivity or other acquired\u002Fcongenital immunodeficiency diseases; history of active autoimmune disease or autoimmune diseases including but not limited to Crohn's disease, ulcerative colitis, autoimmune hepatitis\u002Fenteritis\u002Fvasculitis\u002Fnephritis, etc.; or history of organ transplantation (except corneal transplant).\n  11. Presence or history of autoimmune disease requiring treatment. Subjects with hypothyroidism on stable replacement therapy or Type 1 diabetes mellitus may be eligible.\n  12. Urinalysis showing urine protein ≥ ++, and confirmed 24-hour urinary protein \\> 1.0 g (except for subjects with multiple myeloma).\n  13. Poorly controlled diabetes (Fasting Blood Glucose \\> 10 mmol\u002FL).\n  14. Epilepsy requiring treatment.\n\nII. Tumor-Related Symptoms and Treatment:\n\n* Known central nervous system (CNS) involvement or carcinomatous meningitis; subjects with solid tumors who have received treatment for brain metastases and have been clinically stable for at least 28 days prior to the first dose without requiring steroids or other therapy for brain metastases may be eligible.\n* Prior chemotherapy, targeted therapy, radiotherapy, or other anti-tumor therapy within 4 weeks before the first dose (calculation based on the end date of the last treatment for washout period).\n* Prior allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, or other cell therapies (e.g., Chimeric Antigen Receptor T-cell \\[Chimeric Antigen Receptor T-cell Therapy (CAR-T)\\] therapy).\n* Treatment within 2 weeks prior to the first dose with Chinese patent medicines approved by the National Medical Products Administration (NMPA) with clearly stated anti-tumor indications in their package inserts (including Fufang Banmao Capsule, Kang'ai Injection, Kanglaite Capsule\u002FInjection, Aidi Injection, Yadanzi Oil Injection\u002FCapsule, Xiaoaiping Tablet\u002FInjection, Huachansu Capsule, etc.).\n* Serous cavity (pleural, peritoneal, or pericardial) effusion requiring repeated drainage for symptomatic relief (investigator's judgment), or receipt of therapeutic serous cavity effusion drainage within 2 weeks prior to treatment.\n* Imaging (CT or MRI) showing tumor invasion of major blood vessels, or the investigator judges a high probability of fatal hemorrhage due to tumor invasion of major blood vessels during the study period.\n\nIII. Study Treatment-Related:\n\n* Prior treatment with B-cell lymphoma-extra large (Bcl-xL) inhibitors.\n* History of live attenuated vaccination within 4 weeks prior to the first dose or planned live attenuated vaccination during the study period.\n* Known allergy to any component of the study drug(s).\n* Requirement for or use of strong inhibitors or inducers of Cytochrome P450 3A (CYP3A) within 2 weeks prior to the first dose (medications or food).\n* Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) is not considered systemic treatment.\n* Diagnosis of immunodeficiency or current systemic glucocorticoid therapy (at a dose equivalent to \\>10 mg\u002Fday prednisone or equivalent) or any other form of immunosuppressive therapy (including but not limited to cyclosporine A, tacrolimus, cyclophosphamide, etc.) continued within 2 weeks prior to study treatment initiation. Exceptions include: ① Topical, ocular, intra-articular, intranasal, or inhaled corticosteroids are permitted. ② Short-term use of corticosteroids for prophylaxis (e.g., contrast allergy) or treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction from contact allergen) is permitted.\n* Participation in another anti-tumor drug clinical trial within 4 weeks prior to the first dose or within 5 drug half-lives (whichever is shorter).",{"count":111,"type":22},66,[25],"To explore the safety, tolerability and pharmacokinetics of TQB3142 for injection in subjects with advanced malignant tumors",[115],"Advanced Malignant Tumors",{"date":117,"type":33},"2026-06-23",{"date":119,"type":33},"2026-02-26",{"date":121,"type":22},"2028-06",{"name":39,"class":40},5,{"id":125,"slug":4,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100644329","NCT07663526","Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®","A Multicenter, Single-Arm Study to Evaluate the Effectiveness and Safety of Tabellvi® (Adalimumab) in Chinese Adult Subjects With Moderate to Severe Active Crohn's Disease in the Real-World Setting","Inclusion Criteria:\n\n* The subject must sign the informed consent form.\n* Aged 18 to 70 years inclusive, no gender restriction.\n* Subjects with definite diagnosis of Crohn's disease in accordance with Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (Guangzhou, 2023), presenting moderate to severe active Crohn's disease with inadequate response, intolerance or contraindication to adequate glucocorticoid and\u002For immunosuppressant therapy.\n* Adult patients with Crohn's disease who are prescribed Tabellvi® Adalimumab Injection by physicians following thorough risk-benefit assessment.\n* Female subjects of childbearing potential must agree to use one contraceptive method approved by the investigator.\n\nExclusion Criteria:\n\n* Subjects who are not suitable for treatment with Tabellvi® Adalimumab Injection based on the prescribing information of Tabellvi® Adalimumab Injection and the judgment of the treating physician.\n* Female subjects who are pregnant or breastfeeding, or who plan to become pregnant during the study period.\n* Subjects with hypersensitivity to any component of Tabellvi® Adalimumab Injection.\n* Subjects with active, chronic or recurrent infections, or a medical history of invasive infections (e.g., listeriosis, histoplasmosis).\n* Subjects with active infections requiring intravenous anti-infective therapy within 30 days prior to the first dose, or those who have received oral anti-infective drugs within 14 days prior to the first dose.\n* Subjects with active tuberculosis infection; or latent tuberculosis infection without adequate treatment; subjects infected with human immunodeficiency virus (HIV); subjects positive for hepatitis C virus antibody (HCV Ab) indicating previous or current infection; subjects positive for hepatitis B surface antigen (HBsAg), or positive for total hepatitis B core antibody (total Hepatitis B core Ab) with positive hepatitis B virus (HBV)-DNA polymerase chain reaction test result.\n* Subjects with syphilis infection requiring treatment.\n* Subjects with moderate to severe heart failure (NYHA Class III\u002FIV), recent cerebrovascular accident, or other medical conditions that may put the subject at risk by participating in this study.\n* Subjects with current evidence of dysplasia or a history of malignant tumors (including lymphoma and leukemia), except cured non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma or localized cervical carcinoma in situ.\n* Subjects with a history of demyelinating diseases (including myelitis), or neurological symptoms suggestive of demyelinating diseases.\n* Subjects who have undergone intestinal resection within the past 6 months, or plan to undergo intestinal resection at any time in the future.\n* Subjects receiving total parenteral nutrition (TPN), or planning to receive TPN at any time during the study period.\n* Subjects with an ostomy or an ileal pouch-anal anastomosis (IPAA) pouch.\n* Subjects with internal or external fistulas, except perianal fistulas without abscess.\n* Subjects with known symptomatic obstructive intestinal strictures.\n* Subjects diagnosed with ulcerative colitis or indeterminate colitis.\n* Subjects with any of the following abnormal laboratory or other examination results during the screening period: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 1.5 times the upper limit of the reference range; white blood cell count \\\u003C 3.0×10⁹\u002FL; electrocardiogram (ECG) with clinically significant abnormalities; total bilirubin ≥3 mg\u002FdL (isolated elevated indirect bilirubin caused by Gilbert's syndrome excluded); serum creatinine \\>1.6 mg\u002FdL.\n* Subjects with other clinically significant abnormal laboratory test results (other than those listed above) identified by the investigator during screening.\n* Subjects who have received other tumor necrosis factor-alpha (TNF-α) inhibitor therapy within 12 weeks before receiving the first dose of Tabellvi® Adalimumab Injection.\n* Subjects currently participating in another clinical study.\n* Subjects deemed unsuitable for participation in this trial by the investigator.","70 Years",{"count":132,"type":22},50,[93],"This is a post-marketing real-world study designed to evaluate the efficacy and safety of Tabellvi® (Adalimumab Injection) in Chinese adult subjects with moderate to severe active Crohn's disease via a single-arm trial. A total of 50 subjects are planned to be enrolled. The primary endpoints include the incidence rates of adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs) and serious ADRs, as well as the proportion of subjects achieving clinical remission (CDAI score \\\u003C 150) at Week 26.",[136],"Crohn's Disease","2026-06-17",{"date":117,"type":33},{"date":59,"type":22},{"date":141,"type":22},"2029-03",{"name":39,"class":40},7,{"id":145,"slug":4,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":150,"maxAge":48,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100643323","NCT07633314","A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease","A Multicenter, Randomized, Open-label, Active-controlled Phase II Clinical Trial to Explore the Efficacy and Safety of Different Doses of TQC3927 Inhaled Powder in Patients With Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Sign an informed consent form before the trial to fully understand the purpose, procedure, and possible adverse reactions;\n* Age: 40 years ≤ age ≤ 75 years (calculated from the date of signing the informed consent form), gender not limited;\n* Participants' body mass index (BMI) is within the range of 18\\~30 kg\u002Fm2 (including the borderline), and their weight is ≥45kg;\n* Diagnosed with Chronic Obstructive Lung Disease (COPD) according to the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and symptoms consistent with COPD for at least 1 year before the screening visit (V1);\n* Participants must have discontinued short-acting β2-adrenergic receptor agonist (SABA) for at least 6 hours and short-acting cholinergic receptor antagonist (SAMA) for at least 8 hours before starting any pulmonary function tests;\n* Participants must be current or former smokers with a smoking history of ≥10 pack-years (pack-year: number of packs per day × number of years of smoking, such as 1 pack of 20 cigarettes per day for 10 consecutive years, or 10 cigarettes per day for 20 consecutive years); former smokers are defined as those who have quit smoking for at least 6 months prior to Visit 1. Note: Use of pipes, cigars, and e-cigarettes cannot be used to calculate packs\u002Fyear;\n* Trained participants are able to perform acceptable and reproducible pulmonary function tests according to American Thoracic Society\u002FEuropean Respiratory Society (ATS\u002FERS) 2005 criteria;\n* Participants voluntarily sign informed consent forms and have no plans for pregnancy within 90 days from the start of treatment to the last dose, and voluntarily use medically approved contraception (including with their partners);\n* Trained participants are able to correctly use a pressure metered-dose inhaler (pMDI), dry powder inhaler (DPI) inhaler for drug administration;\n* Participants are able to attend study visits on time and complete the visit content;\n\nExclusion Criteria:\n\n* Participants currently diagnosed with asthma (including asthma with COPD) or with a history of asthma, based on the investigator's judgment;\n* Participants with a current life-threatening COPD history;\n* Participants with concurrent active or clinically significant respiratory illnesses that significantly impact the study;\n* Participants with serious illnesses other than COPD, or abnormalities in laboratory tests, electrocardiograms, medical history, or physical examinations;\n* Participants who have undergone lung volume reduction surgery, lobectomy\u002Fsegmentectomy, or are expected to undergo lung surgery during the study period within 12 months prior to V1;\n* Participants who have developed pneumonia or lower respiratory tract infections requiring antibiotic treatment within 8 weeks prior to V1 or between V1 and V3;\n* Participants with clinically significant abnormalities on chest computed tomography (CT);\n* Participants currently using positive pressure ventilation;\n* Participants requiring long-term oxygen therapy (oxygen therapy time \\> 15 minutes). 10. Individuals undergoing pulmonary rehabilitation;\n* Participants who changed their smoking status (i.e., started or stopped smoking) or began a smoking cessation program within 6 weeks prior to screening;\n* Individuals with unstable or life-threatening heart disease;\n* Individuals using non-selective oral beta-blockers;\n* Individuals with unstable or uncontrolled hypertension;\n* Abnormal values in clinically significant safety laboratory tests determined by the investigator at the screening visit;\n* Positive results for human immunodeficiency virus (HIV); positive results for hepatitis B surface antigen (HBsAg); positive results for hepatitis C virus (HCV) antibody and supporting documentation.\n* Individuals with a confirmed history of neurological or psychiatric disorders, including epilepsy or dementia requiring treatment;\n* Individuals with a history or current condition of neuropsychiatric, respiratory, cardiovascular, digestive, hematopoietic, lymphatic, immune, hepatic or renal insufficiency, endocrine, musculoskeletal, or other diseases;\n* Individuals who have participated in any drug or medical device clinical trial and received a study intervention within 4 weeks or 5 drug half-lives (whichever is longer) prior to screening;\n* Individuals who have lost or donated more than 400 ml of blood within 3 months prior to the trial. 21. Individuals with a known history of drug or food allergies, especially to components similar to the investigational drug;\n* Individuals who have frequently consumed alcohol within the 6 months prior to screening, or who have tested positive for alcohol in a breathalyzer test;\n* Individuals who have received a live attenuated vaccine within 28 days prior to randomization, an inactivated vaccine within 7 days prior to randomization, or are scheduled to receive a vaccine during the study period;\n* Individuals with a history of any organ or systemic malignancy within the past 5 years;\n* Individuals with a history of drug abuse within the past 2 years, or who have tested positive for drug abuse;\n* Individuals assessed by the investigators as unable to discontinue prohibited drugs as specified in the protocol during the screening and treatment phases of this study;\n* Pregnant or lactating women, or female participants with positive pregnancy test results;\n* Individuals with difficulty obtaining venous blood or a history of fainting from needles or blood loss;","40 Years",{"count":152,"type":22},90,[52],"This is a multicenter, randomized, open-label, positive-drug controlled study designed to evaluate the preliminary efficacy and safety of different doses of TQC3927 inhaled powder for short-term treatment of patients with chronic obstructive pulmonary disease, and to observe the symptoms and pharmacokinetic (PK) characteristics of participants.",[156],"Chronic Obstructive Pulmonary Disease","2026-06-03",{"date":159,"type":33},"2026-06-08",{"date":35,"type":22},{"date":162,"type":22},"2027-01",{"name":39,"class":40},15,{"id":166,"slug":4,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},"100624297","NCT07407803","Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","Randomized, Double-Blind, Parallel-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQ-B3234 Capsules Versus Placebo in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","Inclusion Criteria:\n\n* The subject voluntarily joins this study, signs the informed consent form, and demonstrates good compliance.\n* Age ≥18 years (calculated from the date of signing the informed consent form).\n* Diagnosis of symptomatic, non-resectable neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (PN) requiring systemic therapy per investigator judgment.\n* At least one measurable lesion with a dimension ≥3 cm.\n* There should be no significant changes in the use of chronic neuropathic pain medications within 28 days prior to study enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Laboratory tests meet the protocol criteria.\n* Women of childbearing potential must agree to use effective contraception during the study and for 6 months after study completion. A negative serum pregnancy test must be documented within 7 days prior to study enrollment. Men must agree to use effective contraception during the study and for 6 months after study completion.\n\nExclusion Criteria:\n\n* Confirmed or suspected malignant glioma or malignant peripheral nerve sheath tumor (MPNST) (excluding low-grade glioma, optic nerve glioma not requiring systemic therapy or radiotherapy); histological confirmation may be required.\n* History of or concurrent other malignancies within 5 years prior to first dosing.\n* Multiple factors affecting oral drug absorption (e.g., dysphagia, chronic diarrhea, intestinal obstruction, major bowel resection).\n* Adverse reactions from prior anti-tumor therapy not recovered to NCI CTCAE v6.0 grade ≤1, except grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non-clinically significant and asymptomatic laboratory abnormalities, and hypothyroidism stabilized by hormone replacement therapy.\n* Major surgery, significant traumatic injury, or planned major surgery during the study within 4 weeks prior to first dosing; or presence of long-term non-healed wounds or fractures.\n* History of arterial\u002Fvenous thrombotic events (e.g., cerebrovascular accident including transient ischemic attack (TIA), deep vein thrombosis, pulmonary embolism) or other severe thromboembolic events within 6 months prior to first dosing.\n* Active viral hepatitis with poor control.\n* Active syphilis requiring treatment.\n* Active tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or clinically symptomatic active pneumonia.\n* History of substance abuse that cannot be controlled or presence of psychiatric disorders.\n* Planned or prior allogeneic bone marrow or solid organ transplantation.\n* History of hepatic encephalopathy.\n* History of or current retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED), central serous retinopathy (CSR), glaucoma, or other significant ocular abnormalities (e.g., intraocular pressure \\>21mmHg).\n* Inability to undergo MRI and\u002For presence of MRI contraindications.\n* Major cardiovascular disease.\n* Active or uncontrolled severe infection.\n* Renal failure requiring hemodialysis or peritoneal dialysis.\n* History of immunodeficiency, including HIV-positive or other acquired\u002Fcongenital immunodeficiency diseases.\n* History of epilepsy.\n* Tumor-related symptoms and treatment.\n* Known hypersensitivity to study drug excipients.\n* Participation in and use of other PN clinical trial drugs within 4 weeks prior to first dosing.\n* Pregnant or lactating participants.\n* Any other condition that, in the investigator's judgment, poses a serious risk to participant safety or interferes with study completion.",{"count":172,"type":22},177,[174],"PHASE3","This study aims to demonstrate that in subjects with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1, TQ-B3234 capsules significantly improve the objective response rate at Week 24 compared to placebo.",[177],"Plexiform Neurofibroma","2026-05-22",{"date":180,"type":33},"2026-05-27",{"date":182,"type":33},"2026-03-31",{"date":184,"type":22},"2028-12",{"name":39,"class":40},29,{"id":188,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":41},"100639680",{"count":190,"type":22},16,[25],"Primary objective: To evaluate the effect of rabeprazole on the pharmacokinetics of TQ05105 tablets.\n\nSecondary objective: To assess the safety and tolerability of single oral administration of TQ05105 tablets alone and in combination with rabeprazole in healthy study participants.",[28],"2026-05-20",{"date":180,"type":33},{"date":197,"type":22},"2026-06",{"date":37,"type":22},{"name":39,"class":40},{"id":201,"slug":4,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},"100632146","NCT07509892","A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus","A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* Sign a written informed consent form, which must meet the following requirements:\n\n  * Willingness to participate in the study and ability to sign an informed consent form.\n  * Willingness and ability to complete all research-related procedures and site visits.\n* Characteristics of participants in the Systemic Lupus Erythematosus (SLE) trial:\n\n  * Screen for patients with a confirmed diagnosis of SLE dating back to at least 24 weeks prior to the visit.\n  * Diagnosed with systemic lupus erythematosus according to the 2019 classification criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).\n  * Meet one of the following criteria: elevated levels of antinuclear antibodies (ANA) ≥ 1:80, positive results for anti-double-stranded DNA (anti-dsDNA) (positive results include indeterminate results), or positive results for anti-Smith (anti-Sm) antibodies.\n  * Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) score ≥ 8 and clinical SLEDAI-2K score ≥ 4, with involvement of joints and\u002For skin vasculitis and\u002For rash manifestations (Note: Clinical SLEDAI-2K manifestations do not include complement deficiency and positivity for anti-ds-DNA antibodies).\n* Age between 18 and 75 years old (based on the date of signing the informed consent form).\n* Medications for SLE treatment:\n\n  * Prior to the screening visit, there must be a period of background therapy of at least 12 weeks. The therapy must have been administered at a stable dose for at least 4 weeks prior to the screening visit and remain stable until randomization and throughout the duration of the study participation. If antimalarial or immunosuppressive therapy is discontinued prior to the screening visit, the last dose must have been administered at least 4 weeks prior. Detailed information on specific medications is as follows:\n\n    1. Immunosuppressants (can be used only one type; combination use is not permitted): Antimalarial drugs: Hydroxychloroquine (allowed for monotherapy; allowed in combination with one type of immunosuppressant) (maximum 400 mg\u002Fday).\n    2. Duration of clearance when using other immunomodulatory drugs or biologics.\n  * Corticosteroids (CS) (prednisone or equivalent medication) is permitted but not required as background therapy. For trial participants using CS, the dose must be stable for at least 2 weeks prior to the screening visit, not exceed 40 mg\u002Fday during screening, and remain stable prior to randomization. Monotherapy with CS is not permitted.\n  * The requirements for trial participants currently receiving long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are as follows:\n\n    1. The dosage must remain stable for a period of 14 days prior to the screening visit and must remain stable until randomization and throughout the study period. The use of NSAIDs alone is not permitted.\n    2. A maximum of one oral NSAID (at a stable dosage) may be used during the study period.\n    3. The concurrent use of aspirin as a cardiovascular protective agent\u002Fto prevent thrombosis (in addition to other NSAIDs) is permitted throughout the study period, provided that the dosage remains stable.\n* Women of childbearing age must agree to use effective contraceptive measures during the study period and for 6 months thereafter, and undergo a blood pregnancy test that is negative within 7 days prior to enrollment in the study. Men must agree to use effective contraceptives during the study period and for the subsequent 6 months.\n\nExclusion Criteria:\n\n* Conditions other than SLE:\n\n  * drug-induced SLE;\n  * Trial participants with other autoimmune diseases (e.g. multiple sclerosis, psoriasis, inflammatory bowel disease, etc.) were excluded. Test participants with secondary dry syndrome could not be excluded;\n  * Excluded trial participants with overlapping syndromes of SLE, such as systemic sclerosis and mixed associative weaving disease;\n  * In the case of a combination of antiphospholipid syndrome secondary to systemic lupus erythematosus, prior severe blood clots \u002F obstetric complications need to be ruled out; Prophylaxis with low-dose aspirin (50-100 mg \u002F d) in the absence of thrombotic events or obstetric comorbidities and with high-risk antiphospholipid antibody (aPL) characteristics may be included;\n  * Trial participants who had had lupus encephalopathy before screening were excluded;\n  * Excluding active, severe lupus nephritis requiring cytotoxic drugs (CTX) or high-dose CS treatment, excluding lupus pinocytosis, thrombotic microangiopathy; Trial participants with lupus nephritis, but who are currently controlled, may be included;\n* Other medical conditions and medical history;\n\n  * Study participants who are pregnant or breastfeeding;\n  * Evidence of a significant disease \u002F condition or unstable clinical condition (e.g. kidney, Liver, blood, gastrointestinal, endocrine, lung, immune, psychiatric) or locally active infection \u002F infectious disease which, according to medical judgement, will significantly increase the risk of the trial participants if they participate in the study;\n  * Have had any major surgery within 30 days prior to the first dose of the study treatment, or planned to have any surgery during the course of the study;\n  * Cancer or a history of cancer or lymphotrophic disease within the past 5 years (except adequately treated basal cell carcinoma or squamous cell carcinoma with no evidence of recurrence);\n  * Class III or IV congestive heart failure as defined by the New York Heart Association (NYHA) or any recent episode of heart failure resulting in symptoms of NYHA Class III \u002F IV; Or a history of clinically significant ventricular arrhythmia (e.g. persistent ventricular arrythmia , ventricular tremor, sharp twisted ventricular articular arrhythmia) or an arrhythmia that requires continuous anti-arrhythmic medication;\n  * A history of acute coronary syndrome (e.g. myocardial infarction, unstable angina) and \u002F or any major cerebrovascular disease within 24 weeks prior to screening;\n  * Currently or recently (within 3 months prior to randomization) had a gastrointestinal disease, including gastrointestinal surgery, that was likely to affect treatment absorption in the study;\n  * In medical judgment, the trial participants had non-SLE concomitant conditions that may require additional systemic corticosteroid therapy during the study (e.g., asthma);\n  * Severe blood loss (\\> 500 mL) or transfusion within 4 weeks prior to randomization;\n  * It is not possible to take the drugs orally;\n  * Unable to receive venous punctures and \u002F or tolerate venous pathways;\n  * Persons who have a history of substance abuse and cannot quit or who have psychiatric disorders;\n  * Any other medical, spiritual and \u002F or social reasons determined by medical judgement;\n* Previous and combined drug use:\n\n  * Unable to adhere to restricted and prohibited treatments; Unable to comply with the discontinuation requirement;\n  * Use more than one immunosuppressant;\n  * Previous exposure to other TYK2 inhibitors;\n  * Participants who were previously exposed to anti-interferon targeted drug trials such as Anilumab, Rontalizumab, nterferon Alpha Kinoid (INFaKinoid), etc.;\n  * Other research drugs must be discontinued for at least 12 weeks or 5 half-lives (whichever is longer) before screening.\n* Infection Related:\n\n  * Chest radiology within 6 months prior to screening showed the presence of active Tuberculosis (TB) in the trial participants. Test participants who were negative for chest radiology within 3 months prior to screening were eligible to participate in the study:\n  * Hepatitis C, hepatitis B, or human immunodeficiency virus (HIV) infection, characterized by antibodies to hepatitis C (anti-HCV) and all HCV-RNA positive, surface antigens to hepatitis B (HBsAg) positive, core antibodies to the hepatitis A (HBcAb) and all HIV-DNA positive, or HIV antibody screening positive;\n  * is currently receiving any treatment regarding chronic infections;\n  * Persons in need of treatment for syphilis;\n  * Have a congenital or acquired immunodeficiency disorder;\n  * Have a history of repeated infections requiring hospitalization or treatment outside the bowel (muscle or intravenous) and receiving intravenous antibiotics; Or need to be hospitalized and \u002F or given intravenous anti-infective treatment within 30 days of the random, or receive any infection requiring oral anti-infectious treatment within 14 weeks of the random;\n  * Prior history of systemic shingles; Or have two or more recurrent shingles in two years; Or the shingles infection did not completely subside within 12 weeks prior to screening;\n  * Vaccinated live within 90 days of randomization or inactivated within 30 days of randomisation;\n* Abnormalities in physical or laboratory tests:\n\n  * Clinically significant chest X-ray or ECG abnormalities\n  * A laboratory test of clinical significance is abnormal. A screening period laboratory test with abnormal results may be repeated once to confirm abnormal results. If the results are restored to programme acceptable during the screening period without intervention, trial participants may be admitted to the study;\n  * Any other significant laboratory abnormalities that may, in medical judgement, pose an unacceptable risk to the trial participants during the study period;\n* Other exclusion criteria:\n\n  * Have a history of any significant drug allergy (e.g. causing an allergic reaction or causing liver toxicity); He is known to be allergic to the ingredients of research drugs;\n  * those who are unable to comply with the pilot programme;\n  * Persons who are ready to undergo or have previously undergone a heterotopic bone marrow transplant or a solid organ transplant;\n  * In the judgement of the investigator, there is a situation that seriously endangers the safety of the test participants or affects the completion of the study by the test participant.","74 Years",{"count":208,"type":22},198,[52],"To assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.",[212],"Systemic Lupus Erythematosus","2026-05-11",{"date":215,"type":33},"2026-05-12",{"date":217,"type":22},"2026-04",{"date":219,"type":22},"2028-03",{"name":39,"class":40},34,{"id":223,"slug":4,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},"100636751","NCT07569757","Clinical Study of TQB2934 Injection in Relapsed\u002FRefractory Multiple Myeloma","A Randomized, Open-Label, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2934 Injection Versus Investigator-Selected Regimens in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Voluntarily join this study, sign the Informed Consent Form (ICF), and demonstrate good compliance.\n* Aged 18 to 75 years old (as of the date of signing the ICF); gender not limited; Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-2.\n* Expected survival greater than 3 months.\n* Patients with relapsed or refractory multiple myeloma.\n* During or after the most recent treatment, there is evidence of disease progression or failure to achieve remission after the last line of treatment。\n* Measurable disease at screening.\n* Adequate organ function as indicated by laboratory tests meeting the criteria.\n* Women of childbearing potential must agree to use effective contraception during the study and for 12 months after the last dose of study treatment, and agree not to donate eggs for reproduction during this period. Must not be breastfeeding and must have a negative serum or urine pregnancy test within 7 days prior to enrollment. Men who have not had a vasectomy and their female partners of childbearing potential should also agree to use effective contraception during the study and for 12 months after the last dose of study treatment, and agree not to donate sperm during this period.\n\nExclusion Criteria:\n\n* History of other malignancies within 5 years prior to informed consent or concurrent presence of other malignancies. The following exceptions are allowed: other malignancies cured by surgery alone with a disease-free survival (DFS) ≥5 years; cured carcinoma in situ of the cervix, non-melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)\\].\n* Diagnosis of plasma cell leukemia (defined as circulating plasma cells ≥5% in peripheral blood according to standard classification), Waldenström macroglobulinemia, primary light-chain (AL) amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein \\[M protein\\], and skin changes), or solitary plasmacytoma.\n* History of prior anticancer treatment, including but not limited to:\n\n  1. Receipt of chimeric antigen receptor T-cell (CAR-T), Chimeric Antigen Receptor T-Cell Immunotherapy(CAR-T), Chimeric Antigen Receptor Natural Killer Cells (CAR-NK), or other cellular therapies within 3 months prior to randomization;\n  2. Receipt of autologous stem cell transplantation within 3 months prior to randomization;\n  3. Receipt of allogeneic stem cell transplantation within 6 months prior to randomization; subjects must have discontinued all immunosuppressive therapy for ≥6 weeks and have no signs or symptoms of graft-versus-host disease (GVHD);\n  4. Receipt of molecular targeted therapy, investigational drugs, or invasive investigational medical devices within 3 weeks or 5 drug half-lives (whichever is shorter) prior to randomization;\n  5. Receipt of monoclonal antibodies, bispecific antibodies, chemotherapy, etc., within 3 weeks prior to randomization;\n  6. Receipt of proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), localized radiotherapy, palliative radiotherapy, or Chinese patent medicines with antitumor indications approved by the National Medical Products Administration (NMPA) within 2 weeks prior to randomization.\n* Previously refractory to control group drugs, or with contraindications, life-threatening allergic reactions, or intolerance to previous treatments.\n* Receipt of systemic corticosteroids at a cumulative dose ≥140 mg prednisone (or equivalent) within 2 weeks prior to randomization. Topical, ophthalmic, intra-articular, intranasal, and inhaled corticosteroids are excluded from the cumulative dose calculation (see Appendix for dose conversion).\n* Toxicities from prior antitumor therapy have not recovered to baseline or ≤ Grade 1, except for Grade 2 alopecia, non-clinically significant and asymptomatic laboratory abnormalities, and hypothyroidism stabilized by hormone replacement therapy, as judged by the investigator to pose no safety risk.\n* History of Grade ≥3 cytokine release syndrome (CRS) associated with any T-cell redirecting therapy (e.g., CD3-redirecting therapies or CAR-T cell therapy).\n* Presence of conditions affecting intravenous infusion or blood collection, dysphagia, chronic diarrhea, intestinal obstruction, or other active gastrointestinal dysfunction that may interfere with drug administration or absorption.\n* Known central nervous system (CNS) involvement of multiple myeloma (MM), or clinical signs\u002Fsymptoms suggestive of leptomeningeal involvement. If either is suspected, both brain MRI and lumbar puncture cytology must be negative.\n* Major surgery, significant traumatic injury, or planned major surgery during the study treatment period within 4 weeks prior to randomization, or presence of non-healed wounds or fractures (major surgery defined as Grade ≥3 according to the 2022 national surgical classification catalogue).\n* Any severe (≥ CTCAE Grade 3) bleeding or hemorrhagic event within 6 months prior to randomization.\n* Arterial or venous thrombotic events within 6 months prior to randomization, including cerebrovascular events (including transient ischemic attack), deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism (implantable venous port- or catheter-related thrombosis and superficial thrombosis are not considered \"serious\").\n* Active hepatitis or decompensated cirrhosis (Child-Pugh Class B or C)\n* Significant cardiovascular disease.\n* Neurological or psychiatric disorders.\n* Pulmonary diseases, including any of the following:\n\n  1. Current or prior non-infectious pneumonitis requiring corticosteroid treatment (including but not limited to acute respiratory distress syndrome, acute hypersensitivity pneumonitis, drug-related pneumonitis, bronchospasm, acute interstitial pneumonitis, idiopathic pulmonary fibrosis, etc.);\n  2. Known or suspected chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) \\\u003C60% of predicted.\n* Active or uncontrolled infections (≥ CTCAE Grade 2), including bacterial, fungal, or viral infections, such as active pneumonia\u002Fpulmonary infection, syphilis, tuberculosis, or Corona Virus Disease 2019 (COVID-19). Subjects with positive Cytomegalovirus (CMV) DNA or Epstein-Barr virus (EBV) plasma DNA during screening are not eligible.\n* Current or prior autoimmune diseases requiring systemic treatment. Subjects with hypothyroidism on stable replacement therapy, well-controlled type 1 diabetes, or skin diseases not requiring systemic therapy (e.g., vitiligo, psoriasis) are eligible.\n* History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency disorders.\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).\n* Known history of hypersensitivity to humanized monoclonal antibodies, or known allergy, hypersensitivity, or intolerance to any component of the investigational product.\n* Any other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that, in the investigator's opinion, may increase the risk associated with study participation or interfere with interpretation of study results.\n* Investigator considers that the subject is likely to have poor compliance with study participation.",{"count":229,"type":22},260,[174],"This study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed\u002Frefractory multiple myeloma. The estimated total sample size is 260 cases, who will be randomly assigned in a 1:1 ratio to the test group and the control group. The primary objective of the study is to demonstrate the efficacy of TQB2934 for injection compared to the investigator-selected regimen in subjects with relapsed or refractory multiple myeloma (RRMM) by evaluating progression-free survival (PFS).",[233],"Multiple Myeloma","2026-05-07",{"date":236,"type":33},"2026-05-08",{"date":197,"type":22},{"date":239,"type":22},"2030-12",{"name":39,"class":40},49,{"id":243,"slug":4,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":4},"100636347","NCT07564505","Post - Marketing Case Registration Study on the Safety and Efficacy of Adalimumab Solution for Injection in Chinese Pediatric Patients With Moderate - to - Severe Active Crohn's Disease","Inclusion Criteria:\n\n* Age is between 6 years old (inclusive) and 17 years old (inclusive), regardless of gender.\n* Diagnosed as having moderate - to - severe active pediatric Crohn's disease according to the \"Expert Consensus on the Diagnosis and Treatment of Pediatric Inflammatory Bowel Disease 2019\".\n* (3) Pediatric Crohn's disease patients who have been prescribed Adalimumab Solution for Injection by doctors after a full assessment of risks\u002Fbenefits.Both the patient and their guardian must sign the informed consent form. The research protocol\u002Finformed consent form used for data collection and data verification should comply with local laws and regulatory requirements.\n\nExclusion Criteria:\n\n* (1) According to the instruction manual of Adalimumab Solution for Injection and the judgment of the treating physician, the patient is not suitable for treatment with Adalimumab Solution for Injection.\n* (2) Pediatric Crohn's disease patients who have received any live vaccines within 3 months prior to the first dose of Adalimumab Solution for Injection or who plan to receive any live vaccines during the study period.\n* Patients who are participating in other clinical studies. (4) Patients whom the investigator deems unsuitable for participation in this trial.","6 Years","17 Years",{"count":85,"type":22},[93],"This study is a real - world clinical research of adalimumab. The project plans to enroll 30 subjects, aiming to evaluate the incidence of serious adverse events (SAEs) within 12, 26, and 52 weeks after treatment; as well as the incidence of adverse events (AEs), adverse drug reactions (ADRs), adverse events of special interest (AESIs), and serious ADRs at 12, 26, and 52 weeks after treatment.",[253],"Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease","2026-04-29",{"date":256,"type":33},"2026-05-04",{"date":258,"type":22},"2026-05",{"date":141,"type":22},{"name":39,"class":40},{"id":262,"slug":4,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":276,"leadSponsor":277,"locationsCount":278},"100621200","NCT07367529","A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","A Phase Ib\u002FII Clinical Trial to Evaluate the Efficacy and Safety of TQB6411 for Injection in Patients With Advanced Lung Cancer","Inclusion Criteria:\n\n* Subjects voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance;\n* Age between 18 and 75 years (calculated based on the date of signing the informed consent form);\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;\n* Expected survival greater than 12 weeks;\n* At least one measurable lesion according to RECIST v1.1 criteria;\n* Laboratory test results meeting the following criteria (no blood transfusion within 14 days or hematopoietic growth factor administration within 7 days prior to screening):\n\n  1. Hemoglobin (HGB) ≥ 90 g\u002FL;\n  2. Absolute neutrophil count (NEUT) ≥ 1.5×10⁹\u002FL;\n  3. Platelet count (PLT) ≥ 90×10⁹\u002FL;\n  4. Total bilirubin (TBIL) ≤ 1.5×Upper Limit of Normal (ULN);\n  5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN (≤ 5×ULN if liver metastases are present);\n  6. Serum creatinine (CR) ≤ 1.3×ULN or creatinine clearance rate (CCR) ≥ 50 mL\u002Fmin;\n  7. Prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5×ULN (no anticoagulant therapy within the past 2 weeks);\n* Lung cancer confirmed by histology or cytology；\n* Willing to provide qualified tumor tissue samples for immunohistochemical testing, unless the subject has no eligible archived specimens and is unsuitable or refuses re-biopsy;\n* Women of childbearing potential must agree to use effective contraception during the study and for 6 months after study completion, with a negative serum or urine pregnancy test within 7 days before enrollment; male subjects must agree to use effective contraception during the study and for 6 months after study completion (see Section 5.5 for details).\n\nExclusion Criteria:\n\n* History of or concurrent other malignancies, except for: other malignancies treated with surgery alone and achieving ≥5 years of disease-free survival (DFS); or cured carcinoma in situ of cervix, non-melanoma skin cancer, or superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading basement membrane)\\].\n* Diseases affecting intravenous injection or blood sampling.\n* Adverse reactions from prior therapies not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v6.0 grade ≤1, except for: grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non-clinically significant asymptomatic grade 2 laboratory abnormalities, hypothyroidism stabilized with hormone replacement, or other toxicities judged by investigator as non-safety risks.\n* Major surgery (Grade 3 or above per National Surgical Classification Catalog 2022), significant traumatic injury within 4 weeks prior to first dose, planned major surgery during study (except protocol-specified procedures), or presence of unhealed wounds\u002Ffractures.\n* Any bleeding or hemorrhagic events ≥CTCAE grade 3 within 4 weeks prior to first dose.\n* Arterial\u002Fvenous thromboembolic events within 6 months prior to first dose, including: cerebrovascular accidents (including transient ischemic attack (TIA), excluding lacunar infarction), deep vein thrombosis, or pulmonary embolism (implantable venous port- or catheter-related thrombosis or superficial venous thrombosis not considered \"severe\" thromboembolism).\n* Active viral hepatitis with poor control, except: hepatitis B surface antigen (HBsAg)-positive subjects with Hepatitis B virus Deoxyribonucleic acid (HBV DNA) \\\u003C500 IU\u002FmL (2500 copies\u002FmL) who agree to receive anti-HBV therapy throughout study; or hepatitis C virus (HCV)-infected subjects (Hepatitis C Virus Antibody or Ribonucleic Acid positive) with hepatitis C virus Ribonucleic Acid (HCV RNA) ≤ULN continuing approved antiviral therapy.\n* Active syphilis requiring treatment.\n* Active tuberculosis, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced\u002Fradiation pneumonitis requiring treatment, clinically significant active pneumonia, history of interstitial lung disease (ILD) requiring treatment, or current ILD.\n* History of psychotropic drug abuse or mental disorders.\n* Prior or planned allogeneic bone marrow or solid organ transplantation.\n* History of hepatic encephalopathy.\n* Significant cardiovascular diseases including:\n\n  1. Cardiac dysfunction ≥New York Heart Association (NYHA) class II or Left Ventricular Ejection Fractions (LVEF) \\\u003C50% by echocardiography;\n  2. Clinically significant ventricular arrhythmia history (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or arrhythmias requiring continuous antiarrhythmic therapy (subjects with stable atrial fibrillation controlled solely by β-blockers may be included after investigator assessment);\n  3. Unstable angina;\n  4. Myocardial infarction within 12 months;\n  5. Cardio contraction time (QTc) \\>450ms (male) or \\>470ms (female) (if abnormal, measure three times at ≥2-minute intervals and average; corrected by Fridericia or Bazett method);\n  6. Congenital long QT syndrome or family history.\n* Active or uncontrolled severe infection (≥CTCAE grade 2).\n* Renal failure requiring hemodialysis or peritoneal dialysis.\n* Immunodeficiency including HIV positivity or other acquired\u002Fcongenital immunodeficiency diseases.\n* Uncontrolled autoimmune diseases requiring immunosuppressants or systemic corticosteroids (\\>10mg prednisone\u002Fday equivalent) within 7 days prior to first dose.\n* Epilepsy requiring treatment.\n* Poorly controlled diabetes (fasting blood glucose \\>10mmol\u002FL).\n* Tumor-related conditions and treatments:\n\n  1. Chemotherapy, immunotherapy, or small-molecule targeted therapy within 3 weeks prior to first dose or within 5 half-lives (whichever shorter); prior local radiotherapy allowed if: completed \\>4 weeks (\\>2 weeks for brain) before study treatment, and target lesions are outside radiation field or show progression within field;\n  2. National Medical Products Administration (NMPA)-approved traditional Chinese medicines with antitumor indications within 1 week prior to first dose;\n  3. Tumor invading major vessels or judged likely to cause fatal hemorrhage;\n  4. Uncontrolled effusions\u002Fascites requiring recurrent drainage;\n  5. Spinal cord compression, leptomeningeal metastases, or brain metastases with symptoms controlled \\\u003C4 weeks, or requiring steroids\u002Fdehydrating agents within 2 weeks before treatment.\n* Known hypersensitivity to study drug or excipients.\n* Prior treatment with: Epidermal Growth Factor Receptor\u002Fcellular-mesenchymal epithelial transition factor (EGFR\u002Fc-Met)-targeted antibody-drug conjugates (ADCs); or topoisomerase I inhibitors (Non-Small Cell Lung Cancer only) or topoisomerase I inhibitor-based ADCs.\n* Prior EGFR\u002Fc-Met-targeted Monoclonal Antibody (mAbs)\u002Fbispecifics with: ≥grade 4 toxicity, permanent discontinuation due to toxicity, ≥grade 3 infusion reactions, or ≥grade 3 myalgia.\n* Participation in other antitumor clinical trials within 4 weeks prior to first dose.\n* Other conditions judged by investigator to jeopardize subject safety or study completion.",{"count":268,"type":22},465,[25,52],"To evaluate the efficacy and safety of TQB6411 for Injection in subjects with advanced lung cancer",[272],"Advanced Lung Cancer",{"date":274,"type":33},"2026-05-05",{"date":119,"type":33},{"date":184,"type":22},{"name":39,"class":40},37,{"id":280,"slug":4,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":294,"leadSponsor":296,"locationsCount":297},"100635341","NCT07551427","A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate\u002FHigh-risk Myelofibrosis","A Phase II, Single-arm, Open-label, Multicenter Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate\u002FHigh-risk Myelofibrosis","Inclusion Criteria:\n\n1. Voluntary and signed informed consent, good compliance.\n2. Age ≥18 years (at time of signing informed consent); Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2; life expectancy ≥24 weeks.\n3. Diagnosis of primary myelofibrosis (PMF) per World Health Organization (WHO) 2016, or post-polycythemia vera myelofibrosis (post-PV-MF) or post-essential thrombocythemia myelofibrosis (post-ET-MF) per International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria; Janus kinase 2 (JAK2) mutation status not restricted.\n4. Intermediate or high risk per Dynamic International Prognostic Scoring System (DIPSS).\n5. Cohort 1: Renal function classified as normal, mild impairment, or moderate impairment. Cohort 2: Prior Janus kinase (JAK) inhibitor therapy with refractory, relapsed, or intolerant.\n6. Spleen enlargement (except Cohort 1).\n7. Peripheral blood and bone marrow blasts ≤10%.\n8. No growth factors, colony-stimulating factors, thrombopoietin, or platelet transfusion within 2 weeks before first dose; and routine blood parameters meet requirements within 7 days before first dose.\n9. Adequate major organ function within 7 days before first dose per protocol (renal function not restricted for Cohort 1).\n10. Agreement to use effective contraception during the study and for 6 months after; negative pregnancy test for females of childbearing potential; non-lactating.\n\nExclusion Criteria:\n\n1. Prior allogeneic stem cell transplantation, or autologous stem cell transplantation within 3 months before first dose, or planned stem cell transplantation.\n2. Prior treatment with 2 or more Janus kinase (JAK) inhibitors (except Cohort 1).\n3. Prior splenectomy or splenic radiotherapy within 6 months before first dose.\n4. Other malignancies within 3 years before first dose or currently present (exceptions per protocol).\n5. Factors affecting oral drug absorption.\n6. Non-hematologic toxicity from prior therapy not recovered to ≤ grade 1 (excluding hypertension and alopecia).\n7. Major surgery or significant traumatic injury within 4 weeks before first dose.\n8. Congenital bleeding or coagulation disorders.\n9. Arterial\u002Fvenous thrombosis event within 6 months before first dose.\n10. History of substance abuse or mental disorder.\n11. Active or uncontrolled severe infection.\n12. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n13. Grade ≥2 myocardial ischemia or infarction, arrhythmia, QT prolongation, or grade ≥2 congestive heart failure.\n14. Uncontrolled hypertension despite standard therapy.\n15. Renal failure requiring hemodialysis or peritoneal dialysis.\n16. Newly diagnosed pulmonary interstitial fibrosis or drug-related interstitial lung disease within 3 months before first dose.\n17. History of immunodeficiency or organ transplantation.\n18. Epilepsy requiring treatment.\n19. Use of protocol-prohibited myelofibrosis (MF) medications, immunomodulators, or immunosuppressants within specified time before first dose.\n20. Use of Chinese patent medicines with anti-tumor indications approved by National Medical Products Administration (NMPA) within 2 weeks before first dose.\n21. Uncontrolled pleural effusion, pericardial effusion, or ascites.\n22. Live attenuated vaccine within 4 weeks before first dose or planned during the study.\n23. Known hypersensitivity to study drug or excipients.\n24. Diagnosis of active autoimmune disease within 2 years before first dose.\n25. Participation in another interventional clinical trial with investigational drug within 4 weeks before first dose.\n26. Any condition that, in the investigator's judgment, seriously endangers subject safety or interferes with study completion.",{"count":286,"type":22},51,[52],"This is an open-label, single-arm, multi-center phase II study consisting of two cohorts. Cohort 1 evaluates the pharmacokinetics (PK) of TQ05105 in myelofibrosis participants with normal, mild, or moderate renal impairment to guide dosing. Cohort 2 evaluates the efficacy and safety of TQ05105 in participants with intermediate\u002Fhigh-risk myelofibrosis who are refractory, relapsed, or intolerant to prior Janus kinase (JAK) inhibitor therapy.",[28],"2026-04-22",{"date":292,"type":33},"2026-04-24",{"date":258,"type":22},{"date":295,"type":22},"2029-06",{"name":39,"class":40},24,{"id":299,"slug":4,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":304,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":164},"100635091","NCT07548177","Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","To Evaluate the Single-arm, Multi-center Phase II Clinical Trial of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","Inclusion Criteria:\n\n* Only when all the following criteria are met will the subjects be eligible for inclusion in this study:\n\n  1. The subjects voluntarily join this study, sign the informed consent form, and have good compliance;\n  2. ≥14 years old (calculated from the date of signing the informed consent form);\n  3. Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 1;\n  4. Expected survival greater than 12 weeks;\n  5. Pathologically confirmed recurrent and\u002For metastatic or unresectable alveolar soft part sarcoma, without previous systemic treatment;\n  6. Confirmed to have at least one measurable lesion according to RECIST 1.1;\n  7. Laboratory tests meet the following standards:\n\n     1. Hemoglobin (HGB) ≥ 90g\u002FL;\n     2. Absolute neutrophil count (NEUT) ≥ 1.5×109\u002FL;\n     3. Platelet count (PLT) ≥ 100×109\u002FL.\n     4. Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);\n     5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN. If there is liver metastasis, ALT and AST ≤ 5 ULN;\n     6. Serum creatinine (CR) ≤ 1.5 ULN or creatinine clearance rate (CCR) ≥ 60ml\u002Fmin;\n     7. Prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5×ULN (if not receiving anticoagulant therapy);\n     8. Thyroid stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be examined. If T3 and T4 levels are normal, the subject can be included.\n  8. Women of childbearing age must agree to use effective contraceptive measures during the study and for 6 months after the study, and have a negative serum test within 7 days before study enrollment; men must agree to use effective contraceptive measures during the study and for 6 months after the study.\n\nExclusion Criteria:\n\n* Any subject meeting any of the following criteria will be excluded from this trial:\n\n  1. Having had or currently having another malignant tumor within 5 years before the first administration of the drug. The following two situations are eligible for inclusion: other malignant tumors treated with a single surgery and achieving a disease-free survival (DFS) of at least 5 consecutive years; cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)\\].\n  2. Having diseases that affect intravenous injection or blood collection, or having multiple factors that affect oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction, etc.).\n  3. Adverse reactions from previous treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade score of ≤1, except for grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non-clinically significant and asymptomatic laboratory abnormalities, and stable hypothyroidism treated with hormone replacement therapy, which are judged by the investigator to have no safety risks.\n  4. Having undergone major surgery, significant traumatic injury, or expected to undergo major surgery during the study period within 4 weeks before the first administration of the drug (except for surgeries specified in the protocol), or having long-term unhealed wounds or fractures. (Major surgery is defined as: surgeries classified as grade 3 or above in the 2023 version of the surgical classification directory of the participating center).\n  5. Having experienced any bleeding or hemorrhagic event ≥ CTCAE grade 3 within 4 weeks before the first administration of the drug.\n  6. Having experienced an arterial or venous thrombotic event within 6 months before the first administration of the drug, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, and pulmonary embolism.\n  7. Active viral hepatitis that is not well controlled. Subjects meeting the following requirements can be screened: HBsAg-positive subjects must have Hepatitis B Virus (HBV) DNA quantification \\\u003C 2000 IU\u002Fml (or 1\\*104 copies\u002Fml) or have received at least 1 week of antiviral treatment for HBV before the start of the study and have a 10-fold (1 log value) or greater reduction in viral index, and be willing to receive antiviral treatment throughout the study; HCV-infected subjects (HCV Ab or HCV RNA positive): judged by the investigator to be in a stable state or receiving antiviral treatment at the time of enrollment and continuing to receive approved antiviral treatment during the study.\n  8. Active syphilis infection requiring treatment.\n  9. Having active tuberculosis, a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or active pneumonia with clinical symptoms.\n  10. Having a history of substance abuse of psychotropic drugs and being unable to quit or having a mental disorder.\n  11. Preparing for or having previously received allogeneic bone marrow transplantation or solid organ transplantation.\n  12. Having major cardiovascular diseases, including any of the following conditions:\n\n      1. Cardiac insufficiency of New York Heart Association Functional Classification (NYHA) class II or above or echocardiography showing left ventricular ejection fraction (LVEF) \\\u003C 50%;\n      2. History of clinically significant ventricular arrhythmias (such as sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes ventricular tachycardia) or arrhythmias requiring continuous antiarrhythmic drug treatment;\n      3. Unstable angina pectoris;\n      4. Myocardial infarction within 12 months;\n      5. Fridericia-corrected QT interval (QTcF) \\> 450 milliseconds (msec) for men and \\> 470 msec for women (if QTc is abnormal, it can be continuously measured three times with an interval of more than 2 minutes, and the average value is taken);\n      6. History or family history of congenital long QT syndrome. 7) A history of deep vein thrombosis, pulmonary embolism or any other serious thromboembolic event within 3 months prior to randomization (implantable venous access ports or catheter-related thrombosis, or superficial venous thrombosis are not considered \"serious\" thromboembolic events);\n      7. Currently using or having used within 7 days prior to the start of study treatment aspirin (\\>325 mg\u002Fday (maximum antiplatelet dose)), dipyridamole, ticlopidine, clopidogrel, or cilostazol;\n  13. Active or uncontrolled severe infection (≥CTC AE grade 2 infection);\n  14. Renal failure requiring hemodialysis or peritoneal dialysis;\n  15. History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases;\n  16. Subjects who need to use immunosuppressants, systemic or absorbable local hormones for immunosuppression purposes and will continue to do so within 7 days before the first administration (except for glucocorticoids at a daily dose of \\\u003C10 mg prednisone or other equivalent efficacy hormones);\n  17. Patients with epilepsy requiring treatment;\n  18. Tumor-related symptoms and treatment:\n\n      1. Having received treatment with traditional Chinese patent medicines with clear anti-tumor indications in the National Medical Products Administration (NMPA)-approved drug instructions (including Compound Cantharidin Capsules, Kang'ai Injection, Kanglaite Capsules\u002FInjection, Aidi Injection, Brucea javanica Oil Injection\u002FCapsules, Xiaoaiping Tablets\u002FInjection, Chan Su Capsules, etc.) within 2 weeks prior to the start of study treatment;\n      2. Having received previous treatment with immune checkpoint inhibitors targeting PD-1, PD-L1, or Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4);\n      3. Having previously used anti-angiogenic drugs such as bevacizumab, anlotinib, apatinib, lenvatinib, sorafenib, sunitinib, regorafenib, or fruquintinib;\n      4. Having received treatment with drugs with immunomodulatory functions (such as interleukin-2, thymosin, polysaccharides from Lentinus edodes, etc.) within 30 days prior to the start of treatment;\n      5. Not having recovered from the toxicity and\u002For complications of previous interventions to CTCAE ≤ grade 1, except for alopecia and peripheral neuropathy ≤ grade 2. ；\n      6. Imaging studies (CT or MRI) show that the tumor has invaded major blood vessels or the investigator deems that the tumor is highly likely to invade major blood vessels and cause fatal hemorrhage during the subsequent study period;\n      7. Uncontrolled pleural effusion, pericardial effusion or moderate to severe ascites (as judged by the investigator) that requires repeated drainage;\n      8. Known to have spinal cord compression, carcinomatous meningitis, brain metastases with symptoms or symptoms controlled for less than 4 weeks.\n  19. Known to be allergic to the excipients of the study drug.\n  20. Participants who have taken part in and used other anti-tumor clinical trial drugs within 4 weeks before the first administration of the study drug.\n  21. As judged by the investigator, there are serious conditions that endanger the safety of the participant or affect the participant's completion of the study.","14 Years",{"count":306,"type":22},33,[52],"This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).",[310],"Alveolar Soft Part Sarcoma","2026-04-17",{"date":313,"type":33},"2026-04-23",{"date":315,"type":33},"2026-04-02",{"date":317,"type":22},"2028-11",{"name":39,"class":40},{"id":320,"slug":4,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":336,"locationsCount":41},"100630047","NCT07482592","Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors","Phase I Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3205 Capsule in Subjects With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Subjects voluntarily joined the study, signed informed consent form, and with good compliance.\n* ≥18 years old; Eastern Cooperative Oncology Group (ECOG) physical status: 0-1; at least 3 months expected survival period.\n* At least 1 measurable lesion for efficacy evaluation.\n* The function of main organs is normal.\n* Women of childbearing age should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study, and have a negative serum or urine pregnancy test within 7 days before enrollment in the study; Men should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study period.\n\nExclusion Criteria:\n\n* Individuals who have undergone major surgical treatment, significant traumatic injury, or major surgery during the expected study treatment period within 4 weeks prior to the first medication (excluding surgeries specified in the protocol), or have long-term untreated wounds or fractures. (Major surgery is defined as surgery at level 3 or above in the National Surgical Classification Catalogue 2022 edition);\n* Subjects who experience any bleeding or bleeding events ≥ CTC AE grade 3 within 4 weeks prior to the first administration.\n* Active syphilis infected individuals in need of treatment\n* Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;\n* Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation;\n* History of hepatic encephalopathy;\n* Active or uncontrolled infections (≥ CTC AE level 2 infection);\n* Patients with renal failure requiring hemodialysis or peritoneal dialysis;\n* History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases;\n* Individuals with epilepsy who require treatment;\n* Poor control of diabetes (assessed by the investigator);\n* Known to be allergic to research drugs or excipients;\n* Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first medication;\n* According to the researcher's judgment, there is a situation that seriously endangers the safety of the subjects or affects their ability to complete the study.",{"count":326,"type":22},156,[25],"The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3205 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3205 capsules.",[330],"Advanced Malignant Cancer",{"date":332,"type":33},"2026-04-20",{"date":334,"type":33},"2026-04-15",{"date":184,"type":22},{"name":39,"class":40},{"id":338,"slug":4,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":355},"100634383","NCT07538973","A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function","Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function","Inclusion Criteria:\n\nAll subjects must meet all of the following inclusion criteria:\n\n* Provide signed informed consent prior to trial participation and have a full understanding of the trial content, procedures, and potential adverse reactions;\n* Be male or female subjects aged 18 to 65 years (inclusive);\n* Weigh at least 50 kg for males and at least 45 kg for females. Body Mass Index (BMI = weight (kg) \u002F height² (m²)) within the range of 18 to 30 kg\u002Fm² (inclusive of boundary values);\n* Subjects and their partners agree to voluntarily adopt effective contraceptive measures from screening until 6 months after the last dose;\n* Subjects are able to communicate well with the investigators and can complete the study according to the study protocol.\n\nSubjects with normal liver function must also meet the following inclusion criteria:\n\n* Negative test results for Hepatitis B surface antigen and Hepatitis C antibody;\n* Normal liver function test results or abnormal results without clinical significance;\n* Matched with the hepatic impairment group in terms of male-to-female ratio (±1 subject per gender), mean age (±10 years), and mean body weight (±10 kg).\n\nSubjects with hepatic impairment must meet the following inclusion criteria:\n\n* Have a history of or be diagnosed at screening with primary liver disease, including but not limited to: Hepatitis B, Hepatitis C, non-alcoholic fatty liver disease, alcoholic liver disease, etc.;\n* Hepatic impairment is caused by a previous primary liver disease (diagnosed at least 2 weeks prior to screening; excluding oncology patients) and is classified as Child-Pugh Class A or B;\n* Liver function is stable within 2 weeks prior to taking the study drug, as determined by the investigator;\n* No medication for liver disease within 4 weeks prior to screening, or on a stable medication regimen for existing underlying conditions.\n\nExclusion Criteria:\n\nAll subjects who meet any of the following exclusion criteria are not eligible for enrollment:\n\n* Suffering from primary diseases of major organs, including but not limited to gastrointestinal, respiratory, renal, neurological, hematological, endocrine, oncological, immune, psychiatric, or cardiovascular diseases, as determined by the Investigator to be unsuitable for participation in this trial (except for hepatic impairment patients regarding their primary liver disease and complications of hepatic impairment);\n* Physical examination, vital signs, or clinical laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function) show abnormalities of clinical significance, as determined by the Investigator to be unsuitable for participation in this trial (except for hepatic impairment patients regarding their primary liver disease and complications of hepatic impairment);\n* Participated in any drug clinical trial and used any investigational drug within 3 months prior to screening;\n* Tested positive for HIV or syphilis screening;\n* Subjects with conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug (e.g., inability to swallow) or who have undergone gastrointestinal resection that may affect drug absorption, distribution, metabolism, or excretion;\n* Electrocardiogram (ECG) abnormalities of clinical significance (e.g., tachycardia\u002Fbradycardia requiring medication, second- or third-degree atrioventricular block, or other abnormalities deemed clinically significant and unsuitable for participation by the Investigator);\n* Used any CYP3A4 inhibitors (e.g., macrolide antibiotics such as clarithromycin, triazole antifungals such as itraconazole, and HIV protease inhibitors such as lopinavir) or CYP3A4 inducers (e.g., rifampicin, carbamazepine, and phenytoin) within 4 weeks prior to screening;\n* Used any prescription drugs, over-the-counter medications, herbal medicines, or dietary supplements (e.g., vitamins, calcium supplements) within 2 weeks prior to screening, except for medications used by hepatic impairment patients to treat hepatic impairment and its complications;\n* Known allergy to any component of TQ-B3101 capsules, or having an allergic constitution (including a history of drug allergy, prone to rashes, eczema, urticaria, asthma, etc.);\n* Smoked an average of more than 5 cigarettes per day within 3 months prior to screening;\n* Has a history of drug abuse within 3 months prior to screening, or tested positive for urine drug screening;\n* Alcoholic liver disease patients have a history of alcoholism within 12 months prior to screening; other subjects have a history of alcoholism within 3 months prior to screening (average daily alcohol consumption \\> 2 units \\[1 unit = 360 mL beer or 45 mL 40% spirits or 150 mL wine\\]);\n* Donated blood or plasma, lost ≥ 200 mL of blood, or undergone plasmapheresis within 4 weeks prior to screening;\n* Consumed any food or beverage containing alcohol (or tested positive for alcohol breath test 1 day before dosing; alcoholic liver disease subjects consumed any alcohol-containing substances 2 weeks before dosing), grapefruit juice\u002Fpomelo juice, coffee, tea, cola, or chocolate within 1 week before dosing;\n* Creatinine clearance (CLcr) \\\u003C 60 mL\u002Fmin (calculated by the Cockcroft-Gault formula);\n* Female subjects who are lactating or test positive for pregnancy during screening or the trial period;\n* Deemed by the Investigator to have any factors making them unsuitable for participation in this trial.\n\nSubjects with hepatic impairment must also meet the following additional exclusion criteria:\n\n* History of liver transplantation;\n* Experienced hepatic encephalopathy within 30 days prior to screening;\n* Used any medication that may cause acute hepatotoxicity (e.g., halothane and methotrexate) within 3 months prior to screening;\n* Suffered from drug- or virus-induced acute hepatitis within 2 months prior to screening;\n* Experienced a rapid deterioration or Alanine Aminotransferase\u002FAspartate Aminotransferase (ALT\u002FAST) elevation \\> 3 times the upper limit of normal within 2 weeks prior to dosing, as judged by the Investigator;\n* Experienced worsening of hepatic encephalopathy within 30 days prior to dosing;\n* Suffering from diseases affecting bile excretion, such as biliary cirrhosis, hepatic\u002Fbiliary obstruction, or cholestatic liver disease;\n* Patients with liver failure or complications deemed unsuitable by the Investigator, such as hepatic encephalopathy, hepatocellular carcinoma, esophageal-gastric variceal bleeding within 3 months, severe portal hypertension, or history of portosystemic shunt surgery;\n* As judged by the Investigator, having concomitant medications that may potentially affect the evaluation of the pharmacokinetic characteristics of TQ-B3101 and its metabolites.","65 Years",{"count":297,"type":22},[25],"Evaluation of the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects with Impaired Liver Function versus Normal Liver Function",[348],"Lung Cancer","2026-04-13",{"date":332,"type":33},{"date":217,"type":22},{"date":353,"type":22},"2027-09",{"name":39,"class":40},3,{"id":357,"slug":4,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":17,"minAge":362,"maxAge":248,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":372,"leadSponsor":374,"locationsCount":4},"100633687","NCT07529925","A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis","A Multicenter, Open-label Study on the Efficacy and Safety of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Subjects and their guardians must sign an informed consent form. The research protocol\u002Finformed consent form for data collection and data verification should comply with local laws and regulations.\n* Age 4 years ≤ age ≤ 17 years, regardless of gender;\n* Subjects weigh ≥ 15kg;\n* Subjects who respond poorly to local treatment and\u002For phototherapy or are unsuitable for such treatments;\n* Diagnosed with severe plaque psoriasis in children according to the \"Chinese Expert Consensus on the Diagnosis and Treatment of Pediatric Psoriasis (2021)\"\n\nExclusion Criteria:\n\n* Based on the prescribing information of Adalimumab Solution for Injection and the judgment of the treating physician, the subject is not eligible for treatment with Adalimumab Solution for Injection;\n* Subjects who received psoralen combined with long-wave ultraviolet (UVA) therapy within 14 days prior to the screening period, or topical medium-wave ultraviolet (UVB) therapy within 7 days prior to the screening period;\n* Subjects who received non-biological systemic treatments for paediatric psoriasis within 14 days prior to the screening period;\n* Subjects who are currently using or have used other biological Disease-Modifying Antirheumatic Drug treatments within 12 weeks prior to the screening period;\n* Subjects with significantly active psoriasis within 12 weeks prior to enrolment;\n* Subjects who have received any live vaccine within 3 months prior to the first dose of Adalimumab Solution for Injection, or who plan to receive live vaccines during the study;\n* Subjects currently participating in other clinical studies;\n* Subjects deemed unsuitable for participation in this trial by the investigator.","4 Years",{"count":85,"type":22},[93],"This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint being the proportion of participants achieving PASI 75 (PASI score reduction ≥75% from baseline) at week 16.",[367],"Severe Plaque Psoriasis in Chinese Children","2026-04-08",{"date":370,"type":33},"2026-04-14",{"date":258,"type":22},{"date":373,"type":22},"2028-05",{"name":39,"class":40},{"id":376,"slug":4,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":381,"targetDuration":4,"studyType":23,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":391,"locationsCount":392},"100629911","NCT07480824","To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects","Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of TQ05105 in Participants With Mild Hepatic Impairment (Child-Pugh A), Moderate Hepatic Impairment (Child-Pugh B), and Healthy Subjects","Inclusion Criteria:\n\n* Voluntarily participate in the clinical trial and sign the informed consent form, with full understanding of the trial content, procedures, and potential adverse reactions.\n* Patients (including partners) have no pregnancy plans or sperm\u002Fegg donation plans from screening until 6 months after the last dose of the investigational drug, and agree to use effective contraception.\n* Aged 18-75 years (inclusive), regardless of gender.\n* Male participants weigh ≥50.0 kg; female participants weigh ≥45.0 kg. Body mass index (BMI) = weight (kg)\u002Fheight² (m²), with BMI ranging 18.0-32.0 kg\u002Fm² (inclusive).\n* Patients can communicate effectively with investigators and comply with the trial protocol.\n\nAdditional Criteria for Participants with Normal Liver Function:\n\n* Negative serum HBsAg and Hepatitis C Virus (HCV) antibody test results.\n* Weight within ±10 kg of the average weight of groups A\u002FB; age within ±10 years of the average age of groups A\u002FB; gender distribution similar to groups A\u002FB (±1 participant per gender).\n\nAdditional Criteria for Participants with Impaired Liver Function:\n\n* Chronic liver injury caused by primary liver diseases (e.g., hepatitis B\u002FC, non-alcoholic fatty liver disease, alcoholic liver disease) or clinically diagnosed cirrhosis, classified as Child-Pugh Grade A or B.\n* Stable condition within 2 weeks prior to dosing as judged by the investigator.\n* No medication within 4 weeks before screening, or stable treatment regimen for underlying diseases (including liver-protective therapy).\n\nExclusion Criteria:\n\n* History or current diagnosis of severe\u002Fchronic diseases (e.g., digestive, respiratory, neurological, cardiovascular, hematological, endocrine, oncological, immunological, or psychiatric disorders) deemed unsuitable by the investigator (except primary liver diseases and complications in participants with impaired liver function).\n* Conditions affecting drug absorption, distribution, metabolism, or excretion (e.g., dysphagia) or prior gastrointestinal resection impacting these processes.\n* Use of strong\u002Fmoderate CYP3A4, CYP2C9, or CYP2C19 inducers\u002Finhibitors within 4 weeks before screening.\n* Known hypersensitivity to TQ05105 tablet components or allergic constitution (e.g., allergy to ≥2 substances, drug allergy history, or prone to rash\u002Feczema\u002Fasthma).\n* Average daily smoking \\>5 cigarettes within 3 months before screening.\n* Drug abuse history or positive urine drug screen within 3 months.\n* For alcoholic liver disease participants: history of excessive drinking (\\>2 alcohol units\u002Fday) within 1 year; for others: such history within 3 months.\n* Blood donation\u002Floss ≥200 mL or plasmapheresis within 4 weeks before screening.\n* Consumption of alcohol (or positive breath test), grapefruit juice, coffee, tea, cola, or chocolate within 48 hours before dosing.\n* Creatinine clearance (CLcr) \\\u003C60 mL\u002Fmin.\n* Pregnant\u002Flactating women, positive pregnancy test, or unprotected sex within 2 weeks before screening.\n* Positive HIV antibody or Treponema pallidum-specific antibody.\n* Other factors deemed unsuitable by the investigator.\n\nAdditional Exclusions for Normal Liver Function Participants:\n\n* Use of prescription\u002Fnon-prescription drugs, herbal medicines, or supplements (e.g., vitamins) within 2 weeks before screening.\n* The results of physical examination during the screening period, vital signs, clinical laboratory tests (blood cell analysis (five categories), blood biochemistry, coagulation function, urine routine examination with sediment), electrocardiogram, frontal and lateral chest X-rays, abdominal ultrasound (liver, gallbladder, pancreas, spleen), and urinary system ultrasound, etc., which showed abnormal results and were determined by the research doctor to have clinical significance.\n* Patients in other drug trials within 3 months or 5 half-lives (whichever longer) before screening.\n\nAdditional Exclusions for Impaired Liver Function Participants:\n\n* Had a history of liver transplantation;\n* Patients with hepatic coma within 30 days before screening;\n* Patients who had used drugs that might cause acute hepatotoxicity (such as halothane and methotrexate) within 3 months before screening;\n* Patients with acute liver disease caused by drug or viral infection within 2 months before screening;\n* With biliary cirrhosis, liver\u002Fbile duct obstruction, cholestatic liver disease and other diseases affecting biliary excretion;\n* Patients with liver failure or liver cancer, or patients with a history of esophagogastric variceal bleeding, hepatic encephalopathy, severe portal hypertension, or a portasystemic shunt within 1 year before screening who were judged by the investigator to be ineligible for the trial;\n* Patients with abnormal physical examination, vital signs, clinical laboratory tests (blood cell analysis (five classification), blood biochemistry, coagulation function, urine routine and sediment), AFP, electrocardiogram, chest X-ray, echocardiography, abdominal ultrasound (liver, gallbladder, pancreas and spleen), urinary ultrasound, and routine electroencephalogram (EEG) during the screening period and judged by the research doctors as not suitable for the study;\n* Patients with massive ascites on ultrasound during the screening period who were assessed by the investigators as not suitable for the trial;\n* Who participated in and used any investigational drug within 1 month before screening.",{"count":297,"type":22},[25],"This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the safety of the drug in these patients after a single dose.",[28],"2026-04-03",{"date":387,"type":33},"2026-04-06",{"date":389,"type":33},"2026-04-01",{"date":37,"type":22},{"name":39,"class":40},2,{"id":394,"slug":4,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":410},"100632354","NCT07512596","Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia\u002FVentilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria","Randomized, Double-blind, Parallel-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Polymyxin E2 Mesylate Intravenous Infusion Combined With Nebulized Inhalation in the Treatment of Hospital-acquired Bacterial Pneumonia\u002FVentilator-associated Bacterial Pneumonia Caused by Carbapenem-resistant Gram-negative Bacteria","Inclusion Criteria:\n\n* Age ≥ 18 years old (based on the date of signing the informed consent form);\n* The subject (or their guardian) voluntarily signed the informed consent form；\n* Acute pulmonary infection with hospitalization duration exceeding 48 hours or within 7 days after discharge; or acute pulmonary infection patients who have undergone mechanical ventilation via oral or nasal tracheal intubation for at least 48 hours;\n* Chest imaging examination (X-ray or CT) within 72 hours prior to randomization reveals characteristics of new or worsening pulmonary infiltration;\n* At least one of the following physical signs or laboratory abnormalities: ① fever (temperature ≥38℃); ② hypothermia (temperature ≤35℃); ③ elevated peripheral white blood cell count (WBC ≥10×10\\^9\u002FL); ④ decreased white blood cell count (WBC ≤4.5×10\\^9\u002FL); ⑤ more than 15% of immature neutrophils such as band forms in peripheral blood;\n* At least one of the following clinical symptoms is present: ① new or acute worsening of pulmonary symptoms or signs, such as cough, dyspnea, increased respiratory rate (respiratory rate \\> 25 breaths per minute), expectoration, or the need for mechanical ventilation; ② hypoxemia (arterial blood gas oxygen partial pressure below 60 mmHg at standard atmospheric pressure, or a progressive decrease in the ratio of oxygen partial pressure to inspired oxygen concentration (PaO2\u002FFiO2)); ③ deteriorating oxygenation requiring replacement of ventilation support system to improve oxygenation, or a change in the level of positive end-expiratory pressure support; ④ new respiratory secretions requiring suction;\n* A specific carbapenem-resistant Gram-negative bacterium was cultured from qualified lower respiratory tract specimens within the first five days\u002Fscreening period, with in vitro susceptibility testing confirming resistance to carbapenems；\n* Female subjects without reproductive potential must meet at least one of the following criteria: a) cessation of regular menstruation for at least 12 consecutive months; b) having undergone hysterectomy and\u002For bilateral oophorectomy. Female subjects with reproductive potential must have a negative serum pregnancy test result at the screening visit and agree to use reliable contraception throughout the study period;\n* Male subjects must agree to adopt reliable contraceptive measures throughout the entire study period.\n\nExclusion Criteria:\n\n* Those who currently suffer from epilepsy\u002Fmyasthenia gravis or have a history of seizures (excluding febrile seizures in childhood)\u002Fmyasthenia gravis;\n* Those who are undergoing hemodialysis or peritoneal dialysis;\n* Combined infections with other lung microbiota: viral pneumonia, fungal pneumonia, pulmonary tuberculosis, atypical pathogen infections, etc；\n* Current concurrent infection of other parts\u002Forgans;\n* Patients with concurrent refractory septic shock, who still exhibit persistent hypotension despite adequate fluid resuscitation or vasopressor therapy prior to randomization;\n* Individuals with immune deficiency or compromised immune function, including but not limited to: human immunodeficiency virus infection, hematological malignancies, bone marrow transplantation, immunosuppressive therapy, and systemic corticosteroid treatment (defined as a daily dose equivalent to prednisone ≥20mg and a treatment duration \\>14 days);\n* During the screening period, any of the following laboratory abnormalities is present: aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT) levels are more than 5 times the upper limit of normal, or AST and\u002For ALT levels are more than 3 times the upper limit of normal and total bilirubin levels are more than 1.5 times the upper limit of normal, or neutrophil count \\\u003C 1.0×10\\^9\u002FL, or platelet count \\\u003C 60×10\\^9\u002FL; creatinine clearance rate (cLcr) ≤ 50 mL\u002Fmin;\n* Suffering from lung diseases that can interfere with treatment response assessment;\n* Patients with lung abscess, empyema, and mechanical obstructive pneumonia;\n* New York Heart Association (NYHA) class III-IV heart failure;\n* Transplant patients；\n* Patients with an estimated survival time of less than 1 month according to the clinical judgment of the researchers;\n* Those who have allergic reactions to polymyxins or any β-lactams (such as carbapenems, penicillins, monocyclic lactams, cephalosporins);\n* Sbjects requiring \\>2 systemic antimicrobial drugs for the treatment of Gram-negative bacterial infections;\n* Patients with an Acute Physiology and Chronic Health Evaluation II (APACHE II) score greater than 30;\n* Women who are pregnant or breastfeeding;\n* Use potentially effective antibiotics to treat carbapenem resistant gram-negative bacterial infections within 72 hours prior to randomization, and the treatment duration exceeds 24 hours；\n* When the culture results of samples from the first 5 days\u002Fscreening period are available, it is found that the subject has Hospital-Acquired Pneumonia\u002FVentilator-Associated Pneumonia (HAP\u002FVAP) caused by gram-negative bacteria that are expected to have no response to polymyxin drugs;\n* Subjects who have participated in other clinical trials within 30 days prior to the first dose of medication;\n* Other factors determined by the researcher that make the subject unsuitable for participating in this study.",{"count":400,"type":22},48,[52],"Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia\u002FVentilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.",[404],"Hospital-acquired Bacterial Pneumonia\u002FVentilator-associated Bacterial Pneumonia",{"date":387,"type":33},{"date":217,"type":22},{"date":408,"type":22},"2027-07",{"name":39,"class":40},26,{"id":412,"slug":4,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":429,"locationsCount":430},"100617087","NCT07314060","A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2929 Injection in Patients With Acute Exacerbations of Generalized Pustular Psoriasis","Inclusion Criteria:\n\n* Age ≥ 18 or ≤75 years old at screening, regardless of gender;\n* Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as （generalized pustular psoriasis(GPP);\n* Compliant with GPP acute onset;\n* Able to read and understand, and willing to sign the informed consent form;\n* Willing and compliant with study visits and related procedures;\n* Female subjects of childbearing age should agree that contraceptive measures must be used during the study and for 6 months after the end of the study;\n\nExclusion Criteria:\n\n* Pustules are limited to psoriasis vulgaris on psoriasis plaques;\n* Concomitant skin disease or medical disease that may interfere with the investigator's evaluation of the subject's treatment response;\n* Presence of severe, progressive, or uncontrolled disease, or signs and symptoms that are not suitable for participation in the investigator, in the judgment of the investigator:\n* Serum virological abnormalities during the screening period;\n* Chest radiology examination shows that the subject has active tuberculosis or a history of contact with open tuberculosis subjects in the past 6 months or a positive Interferon-Gamma Release Assays(IGRA) test;\n* History of serious infection leading to hospitalization within 2 months prior to baseline;\n* Active infection requiring systemic antibiotics, systemic antifungals, or systemic antiviral therapy within 2 weeks prior to baseline, according to the investigator's assessment;\n* History of opportunistic infection within 6 months prior to baseline;\n* Received live (attenuated) vaccine treatment within 12 weeks prior to baseline;\n* Any major surgery within 4 weeks prior to baseline or planned major surgery during the study;\n* Received blood transfusion within 4 weeks prior to baseline;\n* Participated in clinical trials of other drugs or medical devices within 4 weeks before baseline;\n* Any known or suspected congenital or acquired immunodeficiency state or condition that may compromise the subject's immune status;\n* Subjects with any type of active malignancy or a history of malignancy;\n* Alcohol, drug and known drug dependence;\n* Pregnant or lactating women;\n* Subjects cannot tolerate intravenous infusion administration.",{"count":418,"type":22},36,[52],"This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection\u002Fplacebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.",[422],"Generalized Pustular Psoriasis","2026-03-20",{"date":425,"type":33},"2026-03-24",{"date":427,"type":33},"2026-03-19",{"date":408,"type":22},{"name":39,"class":40},32,{"id":432,"slug":4,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":17,"minAge":150,"maxAge":437,"enrollmentInfo":438,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":451},"100628664","NCT07464587","Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease","Evaluation of Safety Profile in a Cohort Study of Inhaled TQC3721 Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\nCohort A:\n\n* Subjects who have completed the TQC3721-III-01 clinical trial, demonstrated good medication compliance during the 24-week treatment period as required by the protocol (with no major protocol deviations related to medication compliance), and experienced no treatment-related SAEs.\n* Sign the informed consent form and fully understand the trial content, procedures, and potential adverse reactions.\n* Willing and able to comply with the trial arrangements and to use the nebulizer correctly.\n* Subjects have no pregnancy plans from screening until at least 1 month after the last dose of the investigational drug and voluntarily adopt effective contraception measures.\n* Patients with a clear clinical history and related symptoms of COPD (meeting the diagnostic criteria for COPD as outlined in the Chinese Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2021 Revised Edition)).\n\nCohort B:\n\n* Sign the informed consent form prior to screening and fully understand the trial content, procedures, and potential adverse reactions.\n* Willing and able to comply with the trial arrangements and to use the nebulizer correctly.\n* Aged between 40 and 80 years (inclusive), both male and female subjects are eligible.\n* Subjects have no pregnancy plans from screening until at least 1 month after the last dose of the investigational drug and voluntarily adopt effective contraception measures.\n* Patients with a clear clinical history and related symptoms of COPD prior to screening (meeting the diagnostic criteria for COPD as outlined in the Chinese Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2021 Revised Edition)).\n* At the screening visit (V1), post-bronchodilator (salbutamol 4 puffs) lung function shows an FEV1\u002FFVC ratio \\\u003C0.7, and 30% predicted value ≤ FEV1 \\\u003C 80% predicted value.\n* A modified Medical Research Council (mMRC) dyspnea scale score of ≥1 at screening (V1).\n* Subjects on single or dual bronchodilator background therapy (with or without an Inhaled Corticosteroid component) must have been on stable treatment for at least 2 weeks prior to screening.\n* Clinically stable COPD (no moderate or severe COPD exacerbations) within 4 weeks prior to the screening visit (Visit V1).\n* Smoking history of ≥10 pack-years (pack-years: packs per day \\* years of smoking, e.g., 1 pack of 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years) OR a history of exposure to biomass fuels.\n\nExclusion Criteria:\n\nCohort A:\n\n* History of life-threatening chronic obstructive pulmonary disease (COPD) (e.g., prior intensive care unit admission or requiring intubation).\n* Presence of other clinically significant respiratory diseases, such as alpha-1 antitrypsin deficiency, active pulmonary infection, bronchiectasis, interstitial lung disease, pulmonary arterial hypertension, or asthma.\n* Any other systemic disease deemed by the investigator to be clinically significant and not adequately controlled at present.\n* History or current evidence of clinically significant cardiovascular or cerebrovascular disease, specifically including:\n\nMyocardial infarction, unstable angina, or stroke within the past 6 months; Unstable or life-threatening arrhythmia requiring intervention within the past 3 months; New York Heart Association (NYHA) Functional Class III or IV heart failure.\n\n* Poorly controlled hypertension despite medication (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg).\n* Poorly controlled type 2 diabetes mellitus (e.g., fasting blood glucose \\>10 mmol\u002FL).\n* Planned surgery before the end of the study.\n* History of malignancy in any organ system within the past 5 years (except for non-metastatic basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix, with complete remission for \\>5 years prior to screening).\n* Clinically significant laboratory abnormalities at the screening visit (V1) as determined by the investigator, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2 × upper limit of normal (ULN), alkaline phosphatase \\>2 × ULN, or total bilirubin \\>1.5 × ULN.\n* Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.\n* Any other condition considered by the investigator as unsuitable for participation in the study.\n\nCohort B:\n\n* History of life-threatening COPD (e.g., prior intensive care unit admission or requiring intubation).\n* Experienced a COPD exacerbation requiring systemic corticosteroids within 3 months prior to the screening visit (V1).\n* One or more hospitalizations due to COPD exacerbation or pneumonia within 3 months prior to screening.\n* Presence of other clinically significant respiratory diseases, as specified in Criterion A.2.\n* Chest computed tomography (CT) scan showing clinically significant abnormalities not attributable to COPD and judged by the investigator to potentially affect trial evaluation or subject safety.\n* Use of oral theophylline or its derivatives for COPD treatment within 1 week prior to the screening visit (V1).\n* Prior treatment with TQC3721.\n* Any other systemic disease deemed by the investigator to be clinically significant and not adequately controlled at present.\n* History or current evidence of clinically significant cardiovascular or cerebrovascular disease, as specified in Criteria A.4.\n* Poorly controlled hypertension, as specified in Criterion A.5.\n* Poorly controlled type 2 diabetes mellitus, as specified in Criterion A.6.\n* Major surgery (requiring general anesthesia) within 8 weeks prior to the screening visit (V1) with incomplete recovery, or planned surgery before the end of the study.\n* Clinically significant laboratory abnormalities at screening, as specified in Criterion A.9.\n* Positive viral serology: positive for human immunodeficiency virus (HIV) antibody; positive for hepatitis B surface antigen (HBsAg) with hepatitis B virus (HBV) deoxyribonucleic acid (DNA) above the lower limit of quantification of the central laboratory assay; positive for hepatitis C virus (HCV) antibody with confirmed positive HCV ribonucleic acid (RNA); or positive for \\*Treponema pallidum\\* antibody (TPPA).\n* Requirement for long-term daily oxygen therapy (defined as cumulative use \\>12 hours per day).\n* Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.\n* Participation in any other investigational drug or medical device clinical trial within 4 weeks prior to screening, or within 5 half-lives of the previous investigational agent (whichever is longer).\n* Any other condition considered by the investigator as unsuitable for participation in the study.","80 Years",{"count":439,"type":22},800,[174],"To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease",[156],"2026-03-07",{"date":445,"type":33},"2026-03-11",{"date":447,"type":22},"2026-03",{"date":449,"type":22},"2027-04",{"name":39,"class":40},79,{"id":453,"slug":4,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":470,"locationsCount":190},"100579223","NCT06821503","Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","An Open Label Phase Ib\u002FII Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab Plus Chemotherapy in Patients With Advanced Solid Tumors - Cohort C","Inclusion Criteria:\n\n* Age 18 or above.\n* The Eastern Cooperative Oncology Group (ECOG) physical fitness status score is 0-1 points.\n* There should be at least one measurable lesion.\n* All acute toxic reactions caused by previous anti-tumor treatments or surgical procedures have been relieved to grade 0-1 or to the levels specified in the inclusion\u002Fexclusion criteria.\n* Have sufficient organ and bone marrow function\n* Expected survival period ≥ 12 weeks\n* Infertility is defined as women who have reached menopause or have undergone bilateral oophorectomy with medical records. Male participants and female participants with fertility must agree to use one medically approved contraceptive measure during the trial period and within 6 months after the last administration of the trial drug or within 9 months after the last administration of chemotherapy drug (oxaliplatin) (whichever is later). The serum pregnancy test must be negative within 3 days before starting the study medication and not during lactation.\n* With my consent and signed informed consent form.\n* Patients with a pathological diagnosis of pancreatic cancer (ductal adenocarcinoma or adenocarcinoma) have evidence of advanced or metastatic disease that is not resectable.\n* Previously received no systemic treatment for unresectable locally advanced or metastatic pancreatic cancer.\n\nExclusion Criteria:\n\n* Known High-frequency microsatellite instability (MSI-H)\u002Fdeficient mismatch repair (dMMR).\n* There is uncontrolled or symptomatic active central nervous system metastasis, which can manifest as clinical symptoms, cerebral edema, spinal cord compression, cancerous meningitis, leptomeningeal disease, and\u002For progressive growth.\n* Within 14 days prior to enrollment, there were still uncontrollable pleural effusion and ascites despite treatment such as puncture and drainage; Pericardial effusion accompanied by clinical symptoms or moderate or above.\n* Within 14 days prior to enrollment, there is an unresolved biliary obstruction, or the clinical status has remained stable for less than 14 days after biliary stent implantation.\n* Participants' weight has decreased by more than 20% or their body mass index (BMI) is less than 18 kg\u002Fm ² within the first 2 months of enrollment.\n* Received the following treatments or medications before enrollment:\n\n  1. Prior to enrollment, received treatment with C-C chemokine Receptor 8 (CCR8) antibodies, cytotoxic T-lymphocyte associated protein-4 (CTLA-4) antibodies, or other drugs that act on Tregs.\n  2. Having undergone major surgery within 28 days prior to enrollment.\n  3. Used immunosuppressive drugs within 14 days prior to enrollment.\n  4. Vaccination with attenuated live vaccine should be administered within 28 days prior to enrollment or planned within the study period and 60 days after completion of study drug treatment.\n  5. Received anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy, or tumor embolization) within 28 days before enrollment.\n* Diagnosed with any other malignant tumor within the 5 years prior to enrollment.\n* There are any active, known or suspected autoimmune diseases present.\n* Within the first 3 months of enrollment, there have been significant clinical bleeding symptoms or clear bleeding tendencies; Arterial\u002Fvenous thrombotic events that occurred within the first 6 months of enrollment.\n* Significant vascular disease occurred within the first 6 months of enrollment.\n* Severe, unhealed, or cracked wounds, as well as active ulcers or untreated fractures.\n* There is peripheral neuropathy of grade\\>1 present.\n* Have experienced gastrointestinal perforation and\u002For gastrointestinal fistula within the 6 months prior to enrollment;\n* Within the 6 months prior to enrollment, there have been clinical signs or symptoms of intestinal obstruction and\u002For gastrointestinal obstruction.\n* Existence of interstitial lung disease, non infectious pneumonia, or uncontrolled systemic diseases.\n* Known to be allergic to the investigational drug or any of its excipients; Or have experienced severe allergic reactions to other monoclonal antibodies.\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis or co infection with hepatitis B and hepatitis C.\n* Clinical symptoms or diseases of the heart that have not been well controlled:\n* Systemic use of antibiotics for at least 7 days within the 28 days prior to enrollment, or unexplained fever\\>38.5 °C during screening\u002Fbefore first administration.\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Have participated in any other drug clinical studies within 4 weeks prior to enrollment, or have not had more than 5 half lives since the last study medication.\n* Known history of abuse or drug use of psychotropic substances.\n* There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the study results, as well as patients who the researcher deems unsuitable to participate in this study.",{"count":459,"type":22},72,[25,52],"This trial is the cohort C part of a multicenter, open label Phase Ib\u002FII clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid tumors. The dose of LM-108 combined with penpulimab, albumin paclitaxel, and gemcitabine is recommended in Phase Ib.Explore the efficacy and safety of LM-108 combined with anti-tumor therapy in patients with advanced pancreatic cancer in Phase II.",[463],"Advanced Pancreatic Cancer","2026-03-06",{"date":466,"type":33},"2026-03-10",{"date":468,"type":33},"2025-04-11",{"date":184,"type":22},{"name":39,"class":40},{"id":472,"slug":4,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":489},"100549847","NCT06439381","Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps","A Multicenter, Randomized, Continuing Trial to Evaluate the Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps","Inclusion Criteria:\n\n1. Inclusion Criteria of Part A\n\n   * Sign informed consent before the test to fully understand the purpose, process and possible adverse reactions of the test;\n   * Age 18-75 years old (including the threshold), male or female;\n   * Enroll in the clinical study of TQH2722 for chronic sinusitis with or without nasal polyps (study number TQH2722-II-02) and meet the following criteria \"a\" or \"b\" :\n\n     1. Subjects completed prescribed treatment as required and completed Part A end of study (EOS) visit;\n     2. The subjects withdrew early due to poor compliance or other objective reasons other than TQH2722-related AE, and completed the early exit interview according to the plan, and the influencing factors that led to the subjects' early termination of the main study treatment have disappeared\u002Fno longer affected the subjects' participation in the continuation study as assessed by the investigators and sponsors.\n\n   Note: If protocol window period requirements are met, examination results from subject's main study EOS\u002F early exit visit may be used as screening\u002Fbaseline examination for this study.\n   * Subjects had used a more stable dose of nasal glucocorticoids (INCS) for more than 4 weeks prior to screening (for subjects who had used other INCS prior to screening than intranasal Mometasone furoate nasal spray (MFNS), subjects were willing to switch to MFNS during the study);\n   * Subjects agree not to have a family plan for 6 months from the date of signing the informed consent to the last dose, and must use effective non-drug contraception with their sexual partners of childbearing age.\n2. Inclusion Criteria of Part B\n\n   * Sign informed consent before the test to fully understand the purpose, process and possible adverse reactions of the test;\n   * Age 18-75 years old (including the threshold), male or female;\n   * Enroll in the clinical study of TQH2722 for chronic sinusitis with or without nasal polyps (study number TQH2722-II-02) and meet the following criteria \"a\" or \"b\" :\n\n     1. Subjects completed prescribed treatment as required and completed Part B EOS visit;\n     2. The subjects withdrew early due to poor compliance or other objective reasons other than TQH2722-related AE, and completed the early exit interview according to the plan, and the influencing factors that led to the subjects' early termination of the main study treatment have disappeared\u002Fno longer affected the subjects' participation in the continuation study as assessed by the investigators and sponsors.\n\nNote: If protocol window period requirements are met, examination results from subject's main study EOS\u002F early exit visit may be used as screening\u002Fbaseline examination for this study.\n\n* Subjects had used a more stable dose of nasal glucocorticoids (INCS) for more than 4 weeks prior to screening (for subjects who had used other INCS prior to screening than intranasal Mometasone furoate nasal spray (MFNS), subjects were willing to switch to MFNS during the study);\n* Subjects agree not to have a family plan for 6 months from the date of signing the informed consent to the last dose, and must use effective non-drug contraception with their sexual partners of childbearing age.\n\nExclusion Criteria:\n\n* In the main study (TQH2722-II-02), a TQH2722-related SAE occurred or TQH2722-related AE led to the discontinuation of TQH2722 therapy, and after discussion between the investigator and sponsor, the subject was deemed unsuitable for continuation of TQH2722 therapy.\n* The subjects had poor compliance in the main study, and the researchers judged that they could not complete the continuing study.\n* During the main study (TQH2722-II-02), any severe progression or poorly controlled concomitant disease (such as asthma exacerbation requiring adjustment of background medication) is identified and the subject is deemed unfit to participate by the principal investigator;\n* Any of the following laboratory test values are abnormal during the screening period:\n\n  1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5 upper limit of normal (ULN);\n  2. Total bilirubin \\> 2 x ULN (except indirect bilirubin elevation secondary to Gilbert syndrome);\n  3. Creatinine \\> 1.5×ULN;\n* Any medical condition, including but not limited to cardiovascular, gastrointestinal, liver, kidney, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major limb disorders, that the investigator believes is unstable and may affect the patient's safety throughout the study period, or affect the study results or their interpretation, or interfere with the patient's ability to complete the entire study process.For example, but not limited to: ischemic heart disease, left ventricular failure, arrhythmia, uncontrolled hypertension, uncontrolled hyperglycemia, cerebrovascular disease, etc.;\n* Patients with active autoimmune diseases (including, but not limited to, Hashimoto thyroiditis, Graves' disease, inflammatory bowel disease, primary biliary cholangitis, systemic lupus erythematosus, multiple sclerosis and other neuroinflammatory diseases, psoriasis vulgaris, rheumatoid arthritis);\n* Known or suspected immunosuppressed individuals, including but not limited to a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pulmonary cyst disease, aspergillosis), even if the infection has resolved;\n* Subjects with active malignant tumors or a history of malignant tumors:Patients with basal cell carcinoma, skin localized squamous cell carcinoma, or cervical carcinoma in situ who had completed curative treatment for at least 12 months prior to visit 1 could be enrolled in this study; patients with other malignancies could be enrolled if they had completed curative treatment for at least 5 years prior to visit 1;\n* A history of active pulmonary tuberculosis within 12 months prior to screening;\n* Active hepatitis was present at the screening stage, either hepatitis B surface antigen (HBsAg) positive, hepatitis B core antibody (HBcAb) positive and Hepatitis B Virus-DNA positive, or Hepatitis C Virus (HCV) antibody positive and HCV-RNA positive; or human immunodeficiency virus (Anti-HIV) positive, or treponema pallidum antibody (Anti-TP) positive (if the treponema pallidum serological test is positive, then further non-treponema pallidum serological test is performed, the latter is negative and the investigator determines that patients who have been infected with syphilis in the past but have been cured are eligible for inclusion);\n* Diagnosis of helminthic infection within 6 months prior to the screening period, failure to receive standard treatment or failure to respond to standard treatment;\n* Subjects who received the following treatments:\n\n  1. Had sinus surgery or nasal sinus surgery within 6 months prior to screening (visit 1).\n  2. Received monoclonal antibody therapy within 8 weeks or 5 half-lives prior to screening (whichever is longer);\n  3. Received immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporine, interferon gamma, azathioprine, methotrexate, mycophenolate and tacrolimus) within 8 weeks or 5 half-lives prior to screening, whichever is longer;\n  4. Use of other non-biological agents within 8 weeks or 5 half-lives (whichever is longer) prior to screening;\n  5. Intravenous immunoglobulin (IVIG) therapy and\u002For plasma exchange within 30 days prior to screening visit (Visit 1);\n  6. Subjects treated with leukotriene antagonists\u002Fmodulators prior to screening (subjects treated with stable doses of leukotriene modulators for ≥30 days prior to screening can be enrolled);\n  7. Start allergen immunotherapy within 3 months prior to screening, or plan to start such therapy during the study period or plan to change the therapeutic dose during the study period;\n  8. Have received live attenuated vaccine within 4 weeks prior to screening or plan to receive live attenuated vaccine during the study period;\n  9. Chronic active or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasites, antivirals, or antifungals during the 4 weeks prior to screening, or a viral disease that may not have received antiviral treatment during the 4 weeks prior to screening;(Screening visits can be performed after the patient recovers from infection, but the systemic antibiotic washout period needs to be greater than 2 weeks).\n* Patients with asthma should be excluded if: a. forced expiratory volume in the first second (FEV1) ≤ 50% of the expected normal value, or b.Acute exacerbation of asthma within 90 days prior to screening requiring hospitalization (\\>24 hours), or c.Are using a daily dose of fluticasone or equivalent inhaled glucocorticoids (ICS) greater than 1000mcg;\n* Subjects with asthma were initiated with inhaled corticosteroids within 4 weeks prior to the screening\u002Finduction period (for subjects who could receive a stable dose for at least 4 weeks prior to screening and whose assessed dose could be maintained throughout the study period, inhaled corticosteroids could be fluticasone propionate at a dose ≤1000μg or equivalent doses of other inhaled corticosteroids).\n* Subjects have concomitant medical conditions that prevent them from completing the screening period assessment or evaluating the primary efficacy endpoint, such as:\n\n  1. A deviated nasal septum leads to obstruction of at least one nostril\n  2. Persistent drug rhinitis;\n  3. The diagnosis was eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), granulomatous polyvasculitis (Wegener's granuloma), Young's syndrome, Kartagener syndrome or other ciliary dyskinesia syndrome, cystic fibrosis;\n  4. Suspected or confirmed fungal rhinosinusitis on imaging;\n* Subjects with nasal malignancies and benign tumors (e.g., papilloma, hemangioma, etc.);\n* Subjects who are unable to use MFNS or are allergic or intolerant to Mometasone furoate nasal spray;\n* Subjects with a history of systemic allergy to any biological agent (except local injection site reactions);\n* Pregnant or lactating women;\n* Alcohol, drug and known drug dependence;\n* The subjects had poor compliance in the study and could not complete the study as judged by the researcher;\n* Any medical or psychiatric condition that, in the judgment of the investigator or sponsor medical reviewer, puts the subject at risk, interferes with participation in the study, or interferes with the interpretation of the study results.",{"count":478,"type":22},120,[52],"This is a multicenter, randomized, continuing, Phase II expansion trial to evaluate the safety, efficacy, and immunogenicity of two doses of TQH2722 in the long-term treatment of severe chronic sinusitis with or without nasal polyps.",[482],"Chronic Rhinosinusitis",{"date":484,"type":33},"2026-02-27",{"date":486,"type":33},"2024-07-16",{"date":197,"type":22},{"name":39,"class":40},28,{"id":491,"slug":4,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":164},"100588613","NCT06943677","A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsules in Subjects With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Subjects voluntarily joined the study, signed informed consent form, and with good compliance.\n* ≥18 years old; Eastern Cooperative Oncology Group (ECOG) physical status: 0-2; at least 3 months expected survival period.\n* Clearly diagnosed recurrent \u002F refractory hematological tumors that meet the World Health Organization (WHO) definition;\n* At least 1 measurable lesion for efficacy evaluation.\n* The function of main organs is normal.\n* Female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; a negative serum pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped.\n\nExclusion Criteria:\n\n* Patients has had or is currently having other malignant tumors within 3 years. The following two conditions can be included in the group: other malignant tumors treated with a single operation to achieved 5 consecutive years of disease free survival (DFS)s. Cured cervical carcinoma in situ, non-melanoma skin cancer, nasopharyngeal carcinoma and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)\\].\n* Subjects with central nervous system aggression (CNS);\n* Received allogeneic hematopoietic stem cell transplantation (allo-HSCT) or had active graft-versus-host disease (GVHD) requiring immunosuppressive therapy within 12 months before the first dose;\n* Multiple factors that affect the absorption of oral medications (e.g., inability to swallow, chronic diarrhea, and intestinal obstruction);\n* Unrelieved toxicity of ≥CTC AE grade 1 due to any previous treatment, excluding alopecia and fatigue;\n* Major surgical treatment, open biopsy, and significant traumatic injury were received within 28 days before the start of study treatment.\n* The presence of active or uncontrolled primary autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA) and primary immune thrombocytopenia (ITP);\n* Patients with evidence or history of bleeding constitution; Or any bleeding event (such as gastrointestinal bleeding) greater than or equal to CTC AE level 3 within 4 weeks before the first medication;\n* Subjects had an arteriovenous thrombosis event within 6 months.\n* Subjects have history of psychotropic substance abuse and are unable to abstain or have mental disorders;\n* Subjects with any severe and\u002For uncontrolled disease.\n* Within 2 weeks before the first treatment, the subjects had received proprietary Chinese medicines with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions;\n* Previously received treatment with drugs similar to TQB3019 capsules;\n* Uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage (investigator judgment)\n* Study treatment related: subjects received live or messenger RNA (mRNA) vaccines within 4 weeks before the first treatment or were scheduled to receive live or mRNA vaccines during the study;\n* Participated in clinical trials of other antitumor drugs within 4 weeks before the first treatment;\n* According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered unsuitable for enrollment for other reasons.",{"count":497,"type":22},80,[25],"The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3019 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3019 capsules.",[330],"2026-02-10",{"date":81,"type":33},{"date":504,"type":33},"2025-05-26",{"date":184,"type":22},{"name":39,"class":40},""]